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ABSTRACT
Alzheimer's disease (AD) is a neurodegenerative disorder which afflicts over
20 million individuals worldwide. AD is characterized by the presence of insoluble
fibrillar deposits of protein in the brain, in what are known as "amyloid" plaques.
The primary core protein found in these amyloid fibrils is the 39-43 amino acid p
amyloid protein (AP). AP forms amyloid fibrils via a nucleation-dependent
mechanism, resembling that of a crystallization. A structural model for the p34-42
amyloid fibril has been developed using solid state NMR. To test the critical
features of this model, a series of p34-42 peptide mimetics were synthesized as
chemical probes of hydrogen bonding and the proposed cis geometry of the Gly37-
Gly38 amide bond. 1H NMR spectrometry was used to demonstrate that a
hydrophobic cluster, formed by the residues flanking the Gly37Gly38 amide bond,
stabilizes the cis isomer in aqueous solution. A model is presented, based on these
observations, in which hydrophobic cluster formation increases the rate of amyloid
nucleation by stabilizing a key feature of the aggregating conformation.
A 35 amino acid peptide named non-Ap component of AD amyloid (NAC),
is a minor but intrinsic component of AD amyloid plaque and shares a region of
high local sequence homology to Ap. The ability of synthetic NAC to "seed" the
aggregation of p1-40 was investigated. Seeding is a highly specific phenomenon and
requires a significant degree of structural similarity. NAC was shown to seed fibril
formation by Ap and vice versa, suggesting that NAC aggregation may serve as a
pathogenic "trigger" leading to disease. NAC is derived from a precursor protein of
14 kDa, called NACP, which is found in synapses and has been implicated in
learning. We have found that NACP binds specifically to valosin-containing
protein (VCP, also called p97), a cytosolic protein which has been implicated in
protein trafficking, suggesting that NACP may have a function in regulating
synaptic vesicle formation. This finding may have important implications for our
understanding of the molecular basis of learning and its connection to AD.
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Chapter I
Amyloid Proteins in Alzheimer's Disease
In 1906, a German physician described an unusual case of dementia in a
female patient.' The woman, Frau Auguste D., showed symptoms "which could not
be classified under any well-known clinical patterns," beginning with "a strong
feeling of jealousy toward her husband" and progressing to disorientation, severe
memory loss, delirium, and an inability to understand and use language over the
four and a half years until her death at age 55. During autopsy of Frau Auguste's
brain, the doctor utilized a recently developed silver staining technique to discover
the "deposition of a peculiar substance." He also noted significant loss of neurons,
which appeared to have been replaced by "only a tangled bundle of fibrils." The
physician, of course, was named Alois Alzheimer, and the disease which now bears
his name remains nearly as cryptic today as it was to Dr. Alzheimer nearly a century
ago.
Alzheimer's disease (AD) afflicts nearly 4 million individuals in the United
States, and over 20 million worldwide.2 It is the most common form of progressive
dementia in humans, and is increasing in prevalence in developed countries as
lifetimes increase. 3 The risk of acquiring AD increases dramatically in people over
65 years old and continues to increase with age.2 The prevalence of AD is difficult to
determine precisely because of the current lack of definitive objective diagnostic
criteria; however, it is estimated that AD afflicts -~10% of the population over 65 and
nearly 50% of the population over 85.
At present, there is no effective treatment or cure for AD. The inability of
modern medicine to successfully combat this disease stems from a poor
understanding of the factors responsible for causing the disease. Over the last
decade, tremendous advances have been made in defining some of the possible
biological processes and biochemical entities which may play key roles. Only
through the detailed study of these factors will we be able to determine the
molecular basis for AD and, eventually, develop effective strategies for the
treatment of this devastating disease.
AD Pathology
Establishing diagnostic criteria for Alzheimer's disease is difficult because of
the large number of other diseases with similar symptoms of dementia. Although
genetic AD risk factors have been identified, there is no known biological marker
which can be used to make a positive diagnosis. Instead, clinical diagnosis for
probable AD is made by the exclusion of other potential causes. The only true
distinction between AD and other related neurodegenerative disorders is in the
pathology of the AD brain, which can only be determined upon autopsy.
The pathological hallmarks of AD are the presence of insoluble proteinaceous
deposits in the brain, in the form of neurofibrillary tangles and senile plaques.4 In
1963, electron microscopy experiments first revealed the morphology of the
neurofibrillary tangles (NFT) as -10 nm twisted fibrillar structures which were
called "paired helical filaments" (PHF).5 ,6 Immunocytochemical studies at first
suggested that the PHF contained neurofilament proteins.7 However, subsequent
experiments demonstrated that the primary component of the PHF is the
microtubule-associated protein tau.8 The majority of tau found in the PHF is in a
highly phosphorylated state.9 There is no evidence, as yet, for a protein component
other than hyperphosphorylated tau in the PHF.
The senile plaques, on the other hand, are complex lesions comprising a
number of species. Plaques are found not only in AD, but also in patients with
Down's Syndrome (trisomy 21), and, to a lesser extent, in normal aging.4 The
plaques were named "amyloid" (meaning starch-like), because they could be stained
with classic amyloid dyes, such as Congo Red.10 Despite the subsequent
identification of the proteinaceous nature of amyloid deposits,"1 the term has
endured. Plaques consist of a proteinaceous core of amyloid fibrils, surrounded by
dystrophic neurites, activated microglia, and fibrillary astrocytes.4 The amyloid
fibrils of the plaque show morphology which is distinct from that of the PHF; they
are unpaired and -8 nm in diameter. 12 The fibrils do, however, resemble those
found in a number of unrelated systemic disorders, termed "amyloidoses".13
To date, more than 15 normally nonfibrillar proteins have been identified as
forming amyloid fibrils in a number of diverse clinical situations (Table 1.1).13 For
Table 1.1 Precursors of human amyloid fibril proteins
(adapted from reference 13).
Distribution Protein
Systemic Immunoglobulin
Lipoproteins
Transthyretin
Gelsolin
Pancreas Islet Amyloid Polypeptide
Thyroid Calcitonin
Heart Atrial Natriuretic Factor
Musculoskeletal 0-2-microglobulin
Brain P Amyloid Protein
Prion Protein
Cystatin C
Skin Keratin
example, prion protein amyloid is a hallmark of Creutzfeldt-Jakob disease in
humans and its counterpart bovine spongiform encephalopathy ("mad cow
disease") in cattle. 14 A number of systemic diseases are also characterized by
extensive deposition of amyloid, suggestive of a universal pathogenicity of amyloid
deposits. An understanding of the structure and mechanism of amyloid deposition
in AD may therefore provide insight into a wide range of diseases.
The 3 Amyloid Protein and APP Processing
The discovery which has probably had the most profound effect on the
modem era of AD research was the identification in 1984, by Glenner and Wong, of
the primary protein found in the amyloid plaque core.' 5 Amyloid filaments were
isolated from meningeal vessels and solubilized in 6M guanidine hydrochloride.
The N-terminal 24 amino acids were sequenced, and the novel protein was termed
the p amyloid protein (3 protein, AP). The protein has a charged N-terminus and
an extremely hydrophobic C-terminus, which was later shown to extend to 39-43
residues.'6,7
Cloning of A3 cDNAs indicated that the peptide is derived proteolytically
from an integral membrane protein called APP (Amyloid Protein Precursor), which
is encoded by a gene on chromosome 21.16 APP is expressed as several transcripts of
up to 770 amino acids; the most prevalent form contains 695 residues. APP has a
17-residue signal peptide at the N-terminus. Two alternatively spliced exons, of 56
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
Figure 1.1 Amino acid sequence of the 0 amyloid protein (residues 1-42).
and 19 amino acids, are inserted at position 289 (numbers correspond to APP770);
the longer of these contains a serine protease inhibitor domain of the Kunitz type
(KPI). 18 APP has two sites of N-glycosylation (542 and 571), and a single putative
membrane-spanning domain, at residues 700-723.19 Approximately 28 residues of
AP are extracellular, while the last 11-15 amino acids are located within this putative
transmembrane region of APP.
APP is normally processed in a constitutive secretory pathway in which
cleavage occurs at Ap1620 to produce a large secreted derivative and an -8.7 kDa
membrane-associated fragment, neither of which can produce amyloid because they
do not contain the intact AP sequence. This cleavage is carried out by an
unidentified enzyme designated "a-secretase." Based on this data, it was initially
assumed that only aberrant processing under pathological conditions could lead to
the formation of AP and its release from the membrane.
1 695
N C
...ISEVKM I DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA TVIVIT...
t t t
P-secretase a-secretase y-secretase
Figure 1.2 The amyloid precursor protein (APP). The A3 sequence is indicated by
the dark box, and is located partially within the cell membrane. The positions of
APP cleavage by the putative a-, P-, and -secretases are indicated.
It has become evident, however, that only a minority of APP molecules are
processed through this secretory pathway. Full length APP, as well as C-terminal
fragments of APP which contain the complete A3 sequence, have been found
intracellularly within isolated clathrin-coated vesicles. 21 Additionally, surface
antibody and biotinylation experiments have shown that APP can be reinternalized
from the cell surface.22 Together with other supporting experiments, these findings
suggest that full-length APP, as well as some A3-containing fragments, are targeted
to lysosomes for degradation. 23
The discovery that AP-containing fragments of APP are generated under
normal conditions suggested that aberrant processing of APP might not be required
for the production of AP. This concept was supported by the unexpected finding
that AP is secreted into the blood and cerebrospinal fluid of normal, healthy
individuals, and is secreted into the medium of a variety of cultured cells.24-27 APP
proteolysis leads to a heterogeneous population of AP and closely related peptides.
The majority of the peptides produced begin at the N-terminus of AD, Asp-1. 25,26
Minor amounts of peptides which begin at Val-3, Ile-6, Glu-11, or Phe-4 have also
been identified. 25  The C-termini of the A3 peptides produced also varies
considerably. The primary plaque variants are the longer forms, 31-42 and, to a
lesser extent, 01-43.28,29 The shorter variants are prevalent in the circulatory system;
S1-39 is the primary component of cerebrovascular amyloid,17 and 31-40 is found in
the blood and CSF.30 The putative enzymes responsible for N- and C-terminal
cleavage at the AD sequence have been designated P- and y-secretases, respectively.
AD: AD Cause or Byproduct?
A causative role for AP in AD has by no means been proven. However, there
is growing support among AD researchers for a A3 protein amyloid formation as a
critical event in AD pathogenesis. The observation that patients with Down's
Syndrome, who have an extra copy of chromosome 21, invariably develop
pathology resembling that of AD patients strongly supports the hypothesis that the
metabolism of APP into AP may play a critical role in the pathogenesis of disease.31
One significant indication that AP amyloid deposition might be a primary
event in AD is the effect of APP mutations which correlate to early-onset familial
AD (FAD). One such mutation, a double-mutation of K670N/M671L found in a
Swedish family results in a 6- to 15-fold increase in the secretion of AP in cell
culture. 32,33 This mutation is immediately N-terminal to the A3 sequence, and
apparently affects the proteolytic recognition of the P-secretase. This finding
provides a clear link between a familial AD genotype and the generation of AP. The
increased production of AP may lead to a greater extent of fibril formation and, in
turn, an increased risk of AD.
A second set of FAD mutations occurs at position 717, only a few residues C-
terminal to the AP sequence. Unlike the Swedish mutation, these mutations have
no effect on the total production of AP peptides. 33 They do, however, lead to the
production of longer, more readily aggregating peptides,3 3 lending support to the
idea of AP aggregation as a pathogenic event. 34 The significance of "long P"
production is discussed in greater detail later in this chapter.
670, 671 717
• KMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITLVMLv
A¶A
NL (double mutation) I, G, F
Figure 1.3 APP mutations in AD which affect Ap production. Numbering
corresponds to APP770. The AB sequence is indicated in bold.
Support for a pathogenic role for AP has come from the direct demonstration
of its neurotoxicity. Studies of the neurotoxicity of AP were initially plagued by
inconsistent results. AP was shown to have both neurotrophic and neurotoxic
properties depending on the concentration used.35-37 Moreover, different results
were obtained depending on the specific preparation of peptide. Many of these
problems may have stemmed from inconsistencies in the aggregation state of the
peptide. Subsequent work38,39 has helped to clarify this issue, and it is now widely
believed that fibrillar A3 is toxic to cells.
Support for the amyloid hypothesis is growing rapidly, but it has by no means
been universally accepted among AD researchers. Many alternative hypotheses
have been presented. One school of thought, for example, holds that the
neurofibrillary tangles show a more substantive correlation to cases of dementia.40
However, NFTs have also been found in several unrelated neurological disorders
that are not characterized by amyloid deposition and are clinically and pathologically
distinct from AD.4 Additionally, there are documented cases of AD brains with few
tangles which still display plaques and neuronal loss. 41 Most experts in the field, at
least at the present time, agree that plaque formation precedes NFT formation, and
that AP is a more likely candidate for a causal agent.4 Other hypotheses have
focused on neurotransmitter release,42 inflammation, 43 and alternate genetic risk
factors (for example, apolipoprotein E44) as possible pathogenic determinants. It is
likely that no single pathway or event is solely responsible for disease, but that many
factors, either singly or in combination, could have important roles in causing the
complicated pathology of AD.
Structural Studies of Amyloid Fibrils
A primary research interest of this laboratory over the past several years has
been the elucidation of the structure and mechanism of amyloid fibril formation.
Since amyloid fibrils are insoluble and non-crystalline, the traditional methods for
protein structure determination, including X-ray and NMR techniques, have not
been successful in determining amyloid structure. Because of the difficulty in
obtaining information about amyloid structure, the cross-3 fibril, a model proposed
by Pauling in 1955 to describe the structure of Bombyx mori silk,45 has been adopted
as a general model of amyloid structure (Fig. 1.4).12 Clearly this model is
FIBRIL
DIRECTION
Figure 1.4 Structural depiction of the cross-p fibril, as proposed by Pauling et al.45
The antiparallel peptide chains are arranged perpendicular to the direction of fibril
growth to form a p-pleated sheet. Sheets are stacked in a parallel fashion, the
intersheet distance being governed by the identity of the amino acid side chains.
The alignment of the strands relative to each other is not specified.
inadequate for describing individual amyloid structures on a molecular level. Our
laboratory has developed new methods for amyloid structure determination which
utilize our ability to specifically incorporate 13C atoms into the peptide backbone.46-49
The two techniques which have been used are isotope-edited Fourier transform
infrared (FTIR) spectroscopy and rotational resonance solid state NMR spectroscopy
(R2 SSNMR).
In the course of developing a synthetic route to P1-42, it was noted that a C-
terminal nonapeptide, P34-42, was highly insoluble in aqueous media, even in the
presence of 6M guanidinium thiocyanate.49 The peptide formed amyloid fibrils with
a morphology similar to that of the full-length AP found in amyloid plaque. X-ray
diffraction and FTIR experiments revealed that the fibrils had a cross-P
conformation. These initial experiments suggested that the C-terminus of AP might
be important for amyloid formation and inspired structural studies of P34-42.
Isotope-edited FTIR of 134-42 indicated that Va136, Va139, and Val40 are
located in a P-sheet region of the aggregate.48 The terminal residues, L34, I141, and
A42, and the central residues, Gly37 and Gly38, on the other hand, did not appear to
be part of an idealized 1-sheet, and appeared to have an unusual conformation in
the solid state. The conformation of this amide bond was investigated in greater
detail through the use of novel solid state NMR methodology.
Rotational resonance (R2) SSNMR, a technique developed in the laboratory of
Professor Robert Griffin at M.I.T, allows the determination of the distance between
members of a homonuclear spin pair based on rotation-enhanced transfer of
Zeeman magnetization.5 0 This technique can be used to determine distances
between specific carbon atoms in a given peptide by selective pairwise 13C labeling.
These distances can be used to define each dihedral angle in the peptide backbone (0,
xV, co) to allow the systematic elucidation of protein structure. The application of R2
to the structural determination of the 334-42 amyloid fibril has provided important
information about the structure of this peptide, and of amyloid structure in general.
Two standard measurements determine the 0, ', and co dihedral angles, and
therefore the conformation of the peptide backbone. The distance between the a
carbon of one amino acid and the carbonyl carbon of the next (al-2, e.g., a37-38 in
Fig. 1.5) determines the amide bond configuration (o1-2). If al-2 < 4.25 A, then co=0O
(cis) and if al-2 2 4.4 A, then co=180" (trans). Otherwise, both cis and trans
configurations must be considered. The 42 dihedral angle can also be determined
from the al-2 distance. The distance between the carbonyl of amino acid 1 and the a
carbon of amino acid 3 (1a3) depends on the angles 02 and W2, and, in combination
with the al-2 distance, can be used to determine xy2.
Initial R2 experiments on 134-42 focused on defining the geometry at Gly37-
Gly38, the region of the peptide which appeared to have an unusual structure by
FTIR. In initial studies of 134-42, the a37-38 distance was determined to be 4.0 ± 0.2
A, indicating that the Gly37-Gly38 amide bond has the unusual cis configuration. 46
measured: 4.1 - 4.8 A
cis: - 4.25 A
a37-38 trans: - 4.4 A
HrN
_ __ 9I measurea: 4.95 -5.65 AI37a39 idealized P-strand: 5.77 A
Figure 1.5 Distances measured using R2 SSNMR. The possibility of the cis geometry
for Gly37Gly38 was suggested by a37-38, and the compact nature of the 1-sheet was
indicated by 37a39.47
M
Subsequent refinements to the SSNMR simulations, however, indicated that the
effect of inhomogenous line broadening was not fully appreciated in the initial
studies. 47 Consequently, the a37-38 distance was most likely underestimated in the
original work. The improved simulation procedure led to the conclusion that
either the cis or the trans configuration was possible.4 7 Cis amide bonds at other
backbone positions were ruled out by the measured distances.
Using the R2 distances in conjunction with molecular modeling, a library of
possible structures was generated. A significant portion of this library comprised cis
amide-containing structures. A working model for the 034-42 sheet was proposed,
based on the common structural features of this library.47 This model defines
certain critical features of the P sheet. First, the sheet is well-defined with respect to
interstrand orientation; this was not surprising, based on the importance of
interstrand side-chain interactions in P-sheet formation. Second, the sheet appears
to be more highly "pleated" than in the cross-n fibril, a feature which may facilitate
specific stabilizing side-chain interactions. Finally, the Gly-Gly amide backbone
conformation, which may be cis, is another feature which could serve to stabilize
the intermolecular packing interactions in the 034-42 amyloid fibril.
Occurrence of Cis Amide Bonds in Proteins
Non-proline cis amide bonds have been identified in several crystalline
proteins. 51 54 The apparent frequency of their occurrence, however, is much lower
than would be expected based solely on thermodynamics: An estimate of the free
energy difference between cis and trans isomers of approximately 3 kcal/mol would
suggest that 1 out of every 100 peptide bonds should be cis.55 This discrepancy may
be due, at least partially, to the misassignment of peptide bond geometry in crystal
structure determination.52 A 1990 survey of protein crystal structures found 17 non-
proline cis amides; of these, the only sequence to appear more than once was Gly-
Gly.53
In a globular protein, a cis amide must allow the protein to assume a
conformation with stabilizing tertiary interactions to offset the energetic cost of
amide isomerization. Similarly, P34-42, a short peptide which assumes an extended
conformation in the fibrillar aggregate, would have to derive a significant amount
of intermolecular interaction energy through isomerization. One structural feature,
a hydrophobic cluster which could drive amide isomerization and subsequent
aggregation, is described in Chapter 3. It is interesting to note that, in addition to the
currently accepted model for the cross-0 fibril, Pauling also presented two models
with alternating cis and trans peptide bonds. 56
Cis or Trans: A Matter of Angstroms
Although the R2 technique is a very powerful tool for solid-state structure
determination, its application to the determination of amyloid structure is still
undergoing refinements. The experiments described in Chapters 2 and 3 of this
work were carried out in parallel with the R2 work as an independent method for
evaluating the feasibility and the functional consequences of the putative cis
geometry of the Gly37Gly38 amide. Following the completion of these experiments,
a new set of R2 experiments were performed which better account for the effect of
intermolecular interactions. These results57 have led to a reevaluation of the data
and suggest that the a37,38 distance is in the 4.6-4.8A range, restricting the amide
geometry to the trans isomer. Assuming that these values are now correct, this very
recent result obviously affects the interpretation of some of the experiments
described herein. Where possible, this has been incorporated into the appropriate
discussion sections. This reevaluation of the NMR data stresses the importance of
our ability to evaluate the mechanistic consequences of specific structural features.
Mechanism of Amyloid Formation: A Nucleation-Dependent Polymerization.
Amyloid formation in vitro occurs via a nucleation-dependent
polymerization process (Fig. 1.6).58 -60 A similar mechanism characterizes many
common assembly processes, including protein crystallization, microtubule
assembly, flagellum assembly, sickle-cell hemoglobin fibril formation, bacteriophage
procapsid assembly, and actin polymerization. 59 A series of unfavorable equilibria
(Kn) involving intermolecular association events precede formation a "nucleus."
Nucleation is an energetically unfavorable process because the resultant
intermolecular interactions do not outweigh the entropic cost of association. 61 In
order for nucleation to occur, a critical concentration of the monomer must be
exceeded. Following nucleation, addition of monomer to the nucleus becomes
thermodynamically favorable, and fibril growth (Kg) occurs rapidly. The growth
process slows and eventually reaches an equilibrium at the thermodynamic
solubility of the amyloid species.
Experimentally, this process manifests itself as a sigmoidal curve, as
illustrated in Fig 1.7, in which no detectable aggregates are observed during an initial
lag time. During this period, trace amounts of dimer, trimer and eventually n-mer
nucleus
Kn Kg , AMYLOID
SP2 P n Pn+1 - FIBRIL
nucleation growth
Figure 1.6 A mechanistic scheme for nucleation-dependent polymerization of an
AP amyloid fibril. Nucleation is thermodynamically unfavorable (Kn<<1), while
growth is favorable (Kg>>1).
(nuclei) are formed, but the monomer is still the predominant species. This
phenomenon, referred to as "kinetic solubility," can lead to the illusion of an
amyloid peptide being "soluble" when in fact it is simply slow to form nuclei.
As a consequence of this nucleation-dependent mechanism, the
concentration of the aggregating species in solution is critical in controlling the rate
of nucleus formation. The concentration-dependence of the lag time is dependent
on the number (n) of molecules in the nucleus. In fact, the rate of nucleation is
proportional to the concentration raised to the nth power (Cn).62 For example, a 5%
increase in the concentration of the aggregating species, with a nucleus size of 20,
would be expected to lead to a increase in the nucleation rate of (1.05)20, or ~3-fold.
Small changes in concentration can therefore cause disproportionately large
increases in the rate of nucleation.
Amount of
aggregate
Time
Figure 1.7 Kinetics of nucleation-dependent amyloid formation. No aggregates are
observable during nucleation (lag time). Following nucleation, growth is rapid.
Addition of a preformed fibril ("seeding") eliminates the requirement for
nucleation and leads to immediate growth.
A further consequence of the nucleation-dependent mechanism is that
addition of a preformed nucleus will eliminate the need for a nucleation event.
This "seeding" phenomenon is homologous to seeding a crystallization by addition
of a seed crystal.59 However, unlike a crystallization, which can often be "seeded" by
random particulate matter (e.g. dust particles), amyloid nucleation is a highly
sequence-specific event. Only the most minimal sequence differences can be
tolerated; for example, a single amino acid change (Met129 to Val) in PrP118-133
retained the ability to seed, 63 but OsmA, a peptide in which the glycine in the GXXX
repeat of OsmB28-44 was replaced with alanine, was ineffective at seeding OsmB.58
This sequence specificity is most likely due to a structural specificity; the structure of
the seed must provide a complementary growth surface for addition of monomers.
This mechanism has ramifications for the treatment of AD and other
amyloid-characterized diseases. Slowing the rate of amyloid formation, either by
reducing the concentration of the aggregating monomer or by interfering with
nucleation, could be one therapeutic strategy. Compounds that bind and stabilize
the nucleus or its precursors may slow amyloid formation, or compounds which
inhibit addition of monomers to the growing fibril could allow dissolution of the
plaques by normal clearance mechanisms. Alternatively, interfering with the
seeding of amyloid formation by endogenous molecules (vide infra) could be an
effective strategy.
The Position of the C-Terminus of AD3 is Critical
The major physiological variants of AD are heterogeneous in their C-
termini. 24-27  Studies of the in vitro kinetics of amyloid formation by a series of
model peptides corresponding to the different C-terminally truncated isoforms led
to the discovery that the longer variants of AD (026-42 and 326-43) formed fibrils
with no lag time, whereas the shorter variants (026-39 and 026-40) exhibited a lag
time of hours to days prior to the observation of any turbidity (Table 1.2).34 A
similar pattern was observed with full-length A[ (01-39 and [1-42). Furthermore,
fibril formation by "short P" could be seeded by the addition of "long P" fibrils,
suggesting that production of long AP variants may be a pathogenic event.34
Table 1.2 Measured lag times for A[ amyloid
fibril formation. 34 Initial concentrations of
peptide: 200 giM for p26-4x; 20 pgM for 1-4x.
peptide nucleation time
326-43 <30 sec
326-42 <30 sec
026-40 -12 h
326-39 -60 h
[1-42 <30 sec
01-39 -96 h
These in vitro studies were later supported by cell-culture and pathology
experiments. Younkin et al. demonstrated that mutations in APP (V717I and
V717F) which cause early-onset familial AD affect the specificity of the proteolytic
release of AD, resulting in a 1.5 to 1.9-fold increase in the percentage of "long P"
relative to "short p" in cultured cells.33 Studies of pathology provided supporting
evidence for long P as an initially deposited species in senile plaques, 28 and [1-42
was found to be the primary constituent of "diffuse" amyloid, presumed to be the
precursor to senile plaque.28,2 9 Furthermore, Younkin has recently demonstrated
that a mutation on chromosome 14 (corresponding to the presenilin protein S182)
also leads to an increased ratio of long to short Ap. 64 These studies support the idea
of long 0 as a pathological species.
The effect of the C-terminus of A[ on the thermodynamic stability of the
amyloid fibril has also been studied. 65  The C-terminus had little effect on the
observed thermodynamic solubility. Differences in fibril structure were
demonstrated by FTIR, with 026-40 displaying a different 1-sheet structure than 326-
43. A mixture of long and short 3 formed segregated, rather than integrated fibrils,
with thermodynamic properties equivalent to the sum of the individual fibrils.
This suggests that short 0, once formed, could dissolve more rapidly than long P,
making its clearance feasible. Long 0, on the other hand, may be difficult to remove
by standard physiological clearance mechanisms, thereby accentuating its
pathological effect.
The Non-AD Component of AD Amyloid (NAC)
Much of the focus of AD research over the last several years has revolved
around P amyloid. This is primarily due to the presence of AD as the primary
proteinaceous component of the amyloid plaques. A number of other molecules
have also been reported to be associated with isolated plaque amyloid, including
heparan sulfate proteoglycan, 66 immunoglobulins,67 and many acute-phase proteins,
such as al-antichymotrypsin,68 apolipoprotein E,44,69,70 complements, serum amyloid
P,71 gamma-trace peptide, 72 and lysosomal proteinases.73 These components have
been identified on the basis of immunohistochemical studies. There is, however,
no biochemical data demonstrating the presence of these components in amyloid
preparations, raising the possibility that these species might not be intrinsic
components of amyloid, but instead are only peripherally associated with the plaque
core.
In 1993, Ueda et al. identified a second intrinsic component of the plaque
core. 74 Human AD brain was homogenized in the presence of SDS, solubilized in
formic acid, and digested sequentially with CNBr and Achromobacter lyticus
protease I. The resultant peptides were analyzed by HPLC and amino acid
sequencing. The majority of the HPLC peaks had sequences corresponding to AP.
Two additional peaks were detected, and named peptide X (sequence:
EQVTNVGGAVVTGVTAVAQK) and peptide Y (TVEGAGSIAAXXGFV). These
sequences were recovered in essentially identical concentrations and were present at
about 1/10 the concentration of AP fragments. These peptides were hypothesized to
be derived from a larger fragment, which was named NAC, signifying "non-A1
component of AD amyloid" (Fig. 1.8).7 4
Using a piece of cDNA encoding peptide X, a cDNA library was screened in
order to isolate the NAC cDNA. Sequence analysis of the clone revealed a 420-bp
open reading frame encoding a protein of 140 amino acid residues, which was
named NACP (for "NAC precursor protein"). The deduced amino acid sequence
showed that X- and Y-peptide sequences are localized immediately next to each
other in the middle of NACP. 74
Because NAC was isolated using a proteolytic enzyme, it was not possible to
determine the N-terminal amino acid of NAC. However, because no other
fragments of NACP were detected in the SDS-insoluble fraction, the 35 amino acid
sequence was considered to be a minimal NAC sequence, although the full-length
species in plaque might be longer by a few amino acids. 74 The C-terminus of NAC is
not at an endopeptidase cleavage site (C-terminal to lysine residues), and is therefore
unambiguous. Presumably NAC is generated from NACP in vivo by proteolytic
activity. The protease responsible for this cleavage has not been discovered.
H2N-EQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFV-CO 2H
"X" I"Y"
Figure 1.8 The non-A3 component of AD amyloid (NAC). Peptides "X" and "Y"
copurified with AP from human AD amyloid plaque.
Although the authors did not recognize it at the time, the NACP sequence
corresponds to a protein, named a-synuclein, which is a member of a family of
proteins that had previously been identified in Torpedo (electric eel)75 and rat,76 and
was subsequently identified in humans. 77 NACP is a presynaptic protein of
unknown function. Recent studies, however, have suggested roles for NACP in
learning and AD (Chapter 5).78 '79 The biochemical basis for these putative functions,
however, remains a mystery.
Deciphering the Complex Molecular Logic of AD
A growing body of scientific evidence indicates that amyloid deposition may
play a primary role in AD. The first important step toward understanding amyloid
formation is to determine the critical structural features which mediate this process.
Only when the structure of the amyloid fibril can be successfully related to the
mechanism of fibril formation on a molecular level will it become possible to
design therapeutic agents which either bind to amyloid, and serve as diagnostics, or
which disrupt amyloid formation, and thereby serve as treatments for disease. The
initial goal of the experiments described in this work, therefore, was to decipher the
molecular logic underlying AP amyloid fibril formation in AD.
It is becoming clearer with each new discovery related to AD that this disease
is a complex pathophysiological phenomenon. It is therefore important to study the
role of not only A3, but also of other physiological species whose pathological
mechanisms may intersect, either directly or indirectly, with amyloid deposition.
NAC and its precursor NACP are such species, and are the subjects of the latter part
of the work described herein.
Despite the tremendous advances of modern medicine in fighting disease,
AD remains among the most poorly understood, and among the most economically
and emotionally costly, of all the diseases facing the world today. The ultimate goal
of AD research is, of course, the development of effective treatments or cures. The
accomplishment of this goal requires a true understanding of the factors responsible
for the disease.
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Chapter II
Synthesis and Aggregation of 3 Amyloid Peptide Mimetics: Chemical
Probes of Amyloid Aggregation in AD.
Background
A primary goal of medicinal chemistry is to determine the effect of chemical
structure on biological activity. In natural products chemistry, this has for many
years entailed the systematic introduction of alternate substituents via organic
synthesis. Likewise, the field of peptide chemistry has also succumbed to the grasp
of medicinal chemistry.1-4 The systematic replacement of amino acid side-chains
with natural or unnatural groups led to the first generation of such designed peptide
variants, or "peptide mimetics". A natural continuation of this strategy was the
design of peptide mimetics which alter the peptide backbone itself. An enormous
amount of work has gone into the design of new peptide mimetics and the
application of these novel structures as probes of biological activity.1-3 With the
advent of biotechnology, molecular biology has become a driving force behind the
design of therapeutic agents. Accordingly, peptides and proteins have become major
targets for drug design, despite the significant problems associated with such
compounds in terms of low bioavailability, rapid metabolism, and lack of oral
activity. By replacing the polypeptide backbone with peptide mimetic structures,
the medicinal chemist is able to develop biologically active compounds which
simultaneously probe the structural features responsible for binding to biologically
relevant target molecules.
Many peptide bond replacements, or "isosteres", have been used in structure-
activity investigations.3  Table 2.1 lists some of the more common amide
replacements, which are designated by the symbol T, followed by the formula for
the amide replacement. For example, replacement of an amide (-CONH-) with an
alkyl group (-CH 2-CH 2-) would be designated P[CH 2CH 2]. Some of these
replacements increase the flexibility of the linkage (e.g. alkyl, thioalkyl) whereas
others lock the bond into a specific geometry (e.g. alkene). Several amide isosteres
which specifically mimic the geometry of the cis amide isomer have been
developed."-8
Table 2.1 Some common amide backbone
modifications.
amide modification designation
-COCH2- Y[COCH 2]
-COO- Y[COO]
-CH 2CH 2- Y[CH 2CH 2]
-CH=CH- T[(Z)-CH=CH] or
P[(E)-CH=CH]
-COS- Y[COS]
Studies of model peptides have suggested some key structural features of the
AP amyloid fibril.9,10 One prominent feature of the model is the possibility of a cis
amide bond at Gly37Gly38 in the solid state. The body of work on peptide bond
isosteres provided us with a promising method to probe the ability of a cis amide to
facilitate AP3 amyloid formation. To this end, the first part of this chapter describes
the incorporation of cis and trans amide isosteres into the 034-42 fibril, and the
investigation of the effect of these substitutions on the kinetics and
thermodynamics of amyloid fibril formation. Additionally, the general role of
hydrophobicity is addressed through the introduction of alternate amino acids. In
the latter part of this section, the role of specific hydrogen bonds in stabilizing the
amyloid fibril is addressed by the use of amide to ester replacements.
Results and Discussion
Selection and Synthesis of Gly37-Gly38 Amide Isosteres
When selecting an amide bond replacement, it is important to consider the
ability of the surrogate to accurately mimic the steric and electronic properties of the
amide bond. While exact identity is only possible in the case of isotopic
replacements, it is clearly advantageous to mimic the desired conformation as
closely as possible. On the other hand, structural identity is not necessarily a
requirement, and subtle changes could actually enhance the ability of an isostere to
access a key conformation. With these considerations in mind, the isosteres shown
in Fig. 2.1 (1 - 5) were chosen to test the conformational requirements for the
glycylglycine dipeptide in P34-42 amyloid fibril formation.
In the case of P34-42, we required a compound with a fixed "cis" configuration
which would only minimally affect the intermolecular packing interactions in the
amyloid fibril. The trans alkene isostere, Y[(E)-CH=CH] has been successfully
employed to mimic the trans amide configuration,6 but the corresponding cis alkene
is difficult to prepare, due to the ease of cis/trans isomerization during synthesis.5
The 1,5-tetrazole ring Y[CN 4] has been developed as an alternative cis amide bond
mimic, but can be difficult to prepare.'1 A readily prepared, isosteric cis amide
replacement is the 1,2-disubstituted pyrrole analog 7, reported in 1992.8
The pyrrole-based amino acid 7 was synthesized via a published procedure as
shown in Figure 2.2.8 Alkylation of pyrrole-2-carboxaldehyde with iodoacetic acid
led to aldehyde 6. Reductive ammination of 6 in methanol led to the desired amino
acid surrogate 7.
Amino terminal protection of 7 with a tert-butoxycarbonyl (Boc) group (8) has
been reported. 8 This protection strategy has a fatal flaw, as the pyrrole analog is
extremely sensitive to acid, and decomposes under the conditions required for Boc
deprotection. Because of this, chain elongation could only be carried out in the
direction of the C-terminus, leaving the pyrrole analog at the N-terminus of the
resultant peptide. 8 We required a method to incorporate this analog within a
polypeptide chain. To this end, 7 was protected with the base-labile protecting group
fluorenylmethoxycarbonyl (Fmoc), and the resultant N-Fmoc amino acid 9 was
purifed by HPLC. The analog was incorporated into 0334-42 in place of Gly38, using
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Figure 2.1 Amide isosteres used in this work. These compounds were incorporated
into p34-42 in place of the glycylglycine dipeptide moiety.
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solid-phase peptide chemistry. The acid-lability of the analog dictated the use of the
4-hydroxymethyl-3-methoxyphenoxybutyric acid (HMPB) resin, which can be
cleaved under mild acid conditions. The resultant peptide was purifed by reversed
phase HPLC.
In addition to the pyrrole analog, several other isosteres were prepared and
incorporated into P34-42. These compounds, while readily synthesized, most likely
bear less of a steric and electronic resemblance to the amide bond than does the
pyrrole. The use of o-aminomethylphenylacetic acid (2) derivatives as cis amide
surrogates has been reported. 12 The synthesis of 2 was carried out by a simple,
published procedure (Fig. 2.3). 7 Addition of sodium azide to indanone 10 in sulfuric
acid provided the lactam 11. Hydrolysis of the lactam with concentrated HC1
followed by protection of the resultant quaternary amide salt of 12 with Fmoc-
/ NH IC H NaOH(aq) N CO2 H
H + 2 18h, RT H
O 0
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Figure 2.2 Synthesis and protection of cis amide isostere 7.
succinimide led to Fmoc-protected amino acid 13. This analog was incorporated
into I34-42 via solid-phase synthesis.
The incorporation of p-aminobenzoic acid into peptides (i.e. 3) has been
reported.' 3 This compound is a less conservative amide replacement; in addition to
eliminating the peptide bond, when used as a replacement for Gly37-Gly38 it also
restricts another degree of freedom at the glycine a position. This compound is
commercially available, and was easily protected with an Fmoc group and
incorporated into the peptide.
The final amide replacement 4 was chosen for its potential as a trans amide
mimic. As with 3, this analog imposes multiple restrictions upon the peptide
backbone. The parent amino acid 3-aminophenylacetic acid is commercially
available, and, as with 3, was protected with an Fmoc group and incorporated into
P34-42. The replacement of both glycine residues with a-aminoisobutyric acid (Aib,
compound 5) is technically not an amide replacement; however, this peptide is
restricted to the trans configuration due to the steric bulk of the a-methyl groups,
and was therefore included in this study.
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Figure 2.3 Synthesis and protection of 12.
Fibril Formation by Amide Isosteres
Initially, the ability of 1-5 to form amyloid fibrils from a supersaturated
aqueous solution was evaluated. Each of the f34-42 analogs formed amyloid fibrils
as defined 14 by 1) fibrillar structure when viewed under an electron microscope
(EM); 2) staining with the amyloidophilic dye Congo Red; and 3) a FTIR spectrum
dominated by P-sheet structure. EM suggested slight structural differences between
the fibrils, but it is difficult to ascribe the macroscopic fibrillar structure to any
specific molecular influences. The ability of all of these analogs to form amyloid
indicates that the peptide backbone can be modified fairly substantially without
eliminating the ability of the peptide to form fibrils.
Effect of Amide Isosteres on Solubility
The solubility of each analog following an aggregation experiment was
measured by quantitative amino acid analysis (Table 2.2). In theory, assuming the
solution has reached an equilibrium, these values would represent true
"thermodynamic" solubilities. In practice, however, these values should be
interpreted only as "effective" measured solubilities, and are meaningful only as
relative values.
Table 2.2 Measured solubilities of peptides
containing amide backbone modifications.
peptide Solubility (gM)
034-42 26 (±5)
1 8 (±1)
2 12 (±1)
3 4 (+2)
4 25 (±4)
5 30 (±5)
In general, the cis amide mimics were less soluble than the native sequence.
Specifically, the pyrrole and p-aminobenzoic acid derivatives (1 and 3) were highly
insoluble relative to j34-42 itself, as was 2, to a lesser extent. In interpreting these
results, we considered the possibility that the addition of an aromatic ring to the
peptide, as in 3, may alter the solubility not by conformational effects, but simply by
adding hydrophobicity. However, 4, which also contains an aromatic ring, does not
show the same decreased solubility. This "trans" derivative, as well as the all-trans
Aib analog 5, both have comparable solubilities to the native peptide, indicating that
specific molecular details, such as the amide configuration, and not hydrophobicity
in general, are more likely to be responsible for the observed solubility properties.
Effect of Amide Isosteres on Kinetic Solubility
The kinetics of amyloid fibril formation by 034-42 and analogs 1 - 5 under
identical conditions (375 gM, 25'C, 10% DMSO/phosphate-buffered saline (PBS))
were monitored using a turbidity assay. The results are shown in Fig. 2.4. All of the
peptides showed kinetic aggregation profiles consistent with a nucleation-dependent
polymerization process.15 f34-42 alone, as noted before, exhibits no lag time prior to
the onset of aggregation. Cis analogs 1 and 3 also showed no significant lag time
preceding aggregation. This is consistent with the hypothesis that a cis amide
facilitates fibril formation. Ideally, one would expect to observe a decrease in the
nucleation time upon constraining the amide into its aggregating conformation,
however, as 334-42 itself does not exhibit a lag time, this cannot be determined. The
p-aminobenzoic acid analog 2 and the Aib derivative 5 exhibited measurable lag
times, and 5 had a much slower rate of growth than the other derivatives. It appears
that these analogs are unable to access a rapidly aggregating conformation, possibly
due to the limited degrees of freedom in these compounds. In fact, these
compounds may be forming aggregates with totally different conformations, which
may not be energetically favorable in the native peptide, but which become
accessible in the modified analogs. Obviously, the more changes made to the
peptide backbone, the more difficult it will be to infer the underlying structural
explanations for the observed results. It is therefore important not to over interpret
these results; this is illustrated by the supposedly "trans" compound 4, which did
not show a lag time.
Effect of Amino Acid Hydrophobicity
The general role of hydrophobicity of the amino acids in f334-42 was probed by
replacing Va136 and/or Va139 with alanine (Fig. 2.5). The prior set of experiments
suggested that increasing the hydrophobicity of the Gly-Gly amide did not enhance
fibril formation either kinetically or thermodynamically. With the flanking
residues, however, a clear dependence on hydrophobicity was observed, as reflected
by the direct correlation between the number of valines and decreased
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Figure 2.4 Kinetics of Amyloid Formation by I34-42 analogs (375 giM, stirred
continuously). (Left) "cis" amide mimics: (o) P34-42, (*) 1, (0) 2, (,) 3. (Right) "trans"
amide mimics: (.) 4, (0) 5.
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thermodynamic and kinetic solubilities of the peptides shown in Fig, 2.5. This effect
may be due to the stabilizing effect of a hydrophobic cluster, such as that discussed in
detail in Chapter 3.16
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Figure 2.5 Solubility and aggregation kinetics of 034-42 hydrophobicity probes. (0)
LMAGGAVIA (lag time -12,000 s), (o) LMAGGVVIA (lag time -3,000 s), (A)
LMVGGVVIA (034-42, no lag time).
Depsipeptide Analogs of 134-42
The cis amide peptide mimetics described in the first part of this chapter were
designed to probe the importance of the Gly37-Gly38 peptide bond geometry. Initial
efforts focused on this particular amide because of its unusual conformation, as
indicated by FTIR and SSNMR. In addition to the amide configuration, we also
wanted to test the pattern of hydrogen bonds proposed in the model for the 034-42
amyloid fibril. In this model (Fig. 2.6), amide hydrogen bonds stabilize the
intermolecular interactions, with the glycylglycine moiety serving as a flexible
"hinge" to optimize the packing of the 3-sheet.
One strategy which allowed us to test the hydrogen bonding pattern in P34-
42, as well as to further explore the GlyGly amide conformational requirements, was
the replacement of specific peptide bonds with esters. Such "depsipeptides" are
found in numerous naturally occurring linear and cyclic peptides, and have
frequently been used in the study of structure-activity relationships in bioactive
peptides. 17 For example, an oxytocin depsipeptide derivative in which three
supposed intramolecular hydrogen bonding amides were replaced with esters still
H2N'
HO
A42
H2N
Figure 2.6 Proposed model for hydrogen bonding in the 034-42 amyloid fibril.9 The
intermolecular R2 effects (indicated by arrows) constrain the interstrand alignment.
These effects are consistent with a single p-sheet with the indicated hydrogen
bonding pattern.
A42
showed significant activity, suggesting that these hydrogen bonds are not absolute
requirements for activity. 18 The ester to amide replacement affects hydrogen
bonding in two ways, by directly removing a hydrogen bond donor and by altering
the hydrogen bond accepting ability of the carbonyl.
Three depsipeptide analogs of f34-42 were synthesized, in which either the
Val36-Gly37 amide, the Gly37-Gly38 amide, or the Gly38-Val39 amide was replaced
with an ester (denoted "VoG", "GoG", and "GoV", respectively). An examination of
the thermodynamic solubility and kinetics of amyloid formation by these peptides
were used to probe the individual role of each of these amide bonds.
Each of the three depsipeptide analogs formed fibrils from a supersaturated
aqueous solution. In each case, the precipitate exhibited fibrillar structure when
examined with an electron microscope, and could be stained with the
amyloidophilic dye Congo Red. The FTIR spectra of all three depsipeptides are
compared to 334-42 itself in Fig 2.7. All show, as expected, a significant degree of P-
sheet structure. GoG was the most similar to P34-42, with a strong absorbance at
-1631 cm - 1, while the spectra of VoG and GoV showed a broad range of IR bands,
indicative of significant differences in structure from P34-42.
The kinetics of amyloid formation by 134-42 and the three depsipeptide
analogs were compared under identical conditions (375 jiM, 25°C, 10% DMSO/PBS)
(Fig. 2.8). Both 034-42 itself and the GoG analog exhibited no lag time, whereas the
VoG depsipeptide had a short lag time (~ 140 sec) and the GoV peptide had a much
longer delay prior to nucleation (- 5500 sec).
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Figure 2.7 FTIR spectra of f34-42 depsipeptide analogs.
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Figure 2.8 Solubility and aggregation kinetics of depsipeptide analogs of r34-42 (375
gM, stirred continuously at 1550 rpm).
At first we considered the implications of these results in terms of the
putative cis amide at Gly37-Gly38. Peptide GoG formed fibrils with no lag time,
similar to P34-42. The energetic barrier to rotation in an ester is about 10-15
kcal/mol,19 as opposed to - 20 kcal/mol for an amide.20 Thus, all else being equal, if
amide isomerization is rate limiting, this ester replacement should aggregate more
rapidly than 334-42. Since 034-42 itself has no lag time, this was of course impossible
to determine. In any case, the replacement did not slow down the aggregation
process, and is thus consistent with a requirement for an isomerization event.
The aggregation kinetics (Fig. 2.8) can be more easily rationalized in terms of
the putative hydrogen bonding pattern in P34-42. Replacement of the Gly37-Gly38
amide with an ester has no apparent effect on the kinetic solubility of 034-42,
consistent with the proposed role of the glycylglycine as a flexible hinge. The VoG
and GoV analogs, on the other hand, exhibited longer nucleation times. This may
be due to the removal of key hydrogen bonding elements which stabilize the 0-
sheet. In any discussion of hydrogen bonding, it is important to keep in mind the
concept of hydrogen bond "inventory"; that is, the difference between an inter- or
intramolecular H-bond to a peptide versus an intermolecular H-bond to water. It is
likely that introduction of a water molecule into the highly hydrophobic P-sheet is
unfavorable, and that loss of an intermolecular peptide hydrogen bond would have
a negative effect on the stability of the amyloid fibril.
The effect of the depsipeptide replacements on the measured solubility of the
amyloid fibrils is consistent with the above interpretation. The GoG and VoG
peptides had comparable solubilities to P34-42, whereas the GoV peptide, which
exhibited the longest nucleation time, also had the highest solubility. Thus, the
structural features which affect the kinetics of amyloid formation probably have
similar effects on the "thermodynamic" solubility as well.
The depsipeptide analogs provide a tool for the evaluation of the importance
of specific interactions in stabilizing the 034-42 amyloid fibril. Ongoing
investigations into the effect of depsipeptides at the Val39-Val40 and Ile41-Ala42
amides (C. May, unpublished results) should provide further information about
hydrogen bonding patterns in 134-42 and may provide details about the structural
effects of the C-terminal residues which distinguish long and short AD variants.
Experimental Section
Standard Procedures for Peptide Synthesis and Characterization
Peptides were synthesized using either N-Boc or N-Fmoc protected amino
acids and either of the following general procedures, unless specified otherwise, on
either the HMPB-BHA, Wang, 4-hydroxymethylphenylacetamidomethyl (PAM), or
oxime resin. All peptides were prepared with a free amine at the N-terminus and a
free acid at the C-terminus. Amino acid analysis was carried out by the MIT
Biopolymers Laboratory on an Applied Biosystems Model 420 PTH amino acid
analyzer. Peptides LMAGGAVIA and LMAGGVVIA were synthesized and
characterized by J. Chiang, and 334-42 was prepared by T. Ashburn. Analytical HPLC
was performed on a Waters 600E system equipped with a photodiode array detector
using either a Waters (C4, 300A, 15gm, 3.9 x 300 mm) or a Vydac 214TP (C4, 5 mm,
4.6 x 250 mm) reversed phase column. Semipreparative HPLC was performed using
a YMC (C4, 300A, 10gm, 20 x 250 mm) column. Preparative HPLC was performed on
a Waters PrepLC4000 system using a PrepPak C4 cartridge.
N-Boc amino acids. (1) Wash resin with CH 2C12 (2x) followed by iPrOH (2x),
repeat 3x; (2) remove a small amount of resin and perform the Kaiser test for free
amine 21 (the test should be positive (blue)); (3) wash with DMF (3x); (4) add Boc-
amino acid (3 eq, 0.1M in DMF), benzotriazol-yl-oxy-tris-(dimethylamino)
phosphonium hexafluorophosphate (BOP) or an equivalent amount of
benzotriazol-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBOP) (3
eq, 0.1M in DMF), and diisopropylethylamine (DIEA) (5.3 eq), shake resin for 30 sec,
shake mixture for at least 40 min at room temperature (RT); (5) wash with DMF (3x);
(6) wash with CH 2Cl 2 (2x), iPrOH (2x), CH 2C12 (2x); (7) remove a small amount of
resin and perform the Kaiser test for free amine. If positive (blue) then repeat steps
(3) - (7) until a negative (yellow) result is obtained; (8) add acetic anhydride (10 eq)
and DIEA (5 eq) in CH 2C12, and shake for >20 min; (9) wash with CH 2C12 (3x); (10)
add 25% trifluoroacetic acid (TFA) in CH 2C12 and shake for 30 min. Repeat steps (1) -
(10), ending with deprotection of the N-terminal amino acid. (11) Acetylate the N-
terminal amino acid via steps (6) - (9).
N-Fmoc amino acids. (1) Wash resin with DMF (3x), CH 3OH (3x), CH 2C12
(3x); (2) remove a small amount of resin and perform the Kaiser test for free amine
(the test should be positive (blue)); (3) wash with DMF (3x); (4) add Fmoc-amino acid
(3 eq, 0.1M in DMF), BOP reagent (3 eq, 0.1M in DMF) and DIEA (5.3 eq), shake resin
for 30 sec, shake mixture for at least 40 min at RT; (5) wash with DMF (3x); (6) wash
with CH 2C12 (2x), CH 30H (2x), CH 2C12 (2x); (7) remove a small amount of resin and
perform the Kaiser test for free amine. If positive (blue) then repeat steps (3) - (7)
until a negative (yellow) result is obtained; (8) add acetic anhydride (10 eq) and DIEA
(5 eq) in CH 2C12, and shake for >20 min; (9) wash with CH2C12 (3x); (10) add 50%
piperidine in DMF and shake for 30-45 min. Repeat steps (1) - (10), ending with
deprotection of the N-terminal amino acid. (11) Acetylate the N-terminal amino
acid via steps (6) - (9).
Standard Procedure for Trifluoroacetic Acid (TFA) Deprotection
Dried peptide-resin was placed in a flask under Ar. Ethanedithiol (300 gL/g
resin) and thioanisole (200 jgL/g resin) were added, and the reaction was stirred at
O0C for 10 min. TFA (9.5 gL/g resin) was added, and the reaction was stirred at room
temperature for 2h. The resin was removed by filtration, and the TFA solution was
added to cold ether, resulting in precipitation. The pellet was collected by
centrifugation (2000 x g, 10 min), washed 3x with ether and lyophilized to dryness.
Synthesis and Characterization of Glycylglycine Dipeptide Isosteres
2-Formyl-l-pyrrolylacetic acid (6).8 To a solution of 0.92 g (23 mmol, 2.2 eq) of
NaOH in H20 (5 mL) was added 1.0g (10.5 mmol, 1 eq) of pyrrole-2-carboxaldehyde,
and the reaction was stirred at 0"C until the solute had dissolved. Iodoacetic acid
(2.15 g, 11.6 mmol, 1.1 eq) was added and the reaction was warmed to RT and stirred
for 15.5 h. The aqueous solution was washed with CHC13, acidified to pH 3 with 6M
HC1, and extracted with EtOAc. The organic layer was dried over MgSO4, filtered,
and concentrated in vacuo. The product was purified by flash column
chromatography on silica gel (30% EtOAc/hexane, 1% acetic acid) to give 581 mg
(36%) of an off-white solid. 1H NMR (250 MHz, CDC13) 8 9.55 (s, 1H, -CHO), 7.22 (dd,
1H, J= 8Hz, 2Hz, pyrrole -CH), 6.96 (m, 1H, pyrrole -CH), 6.33 (dd, 1H, J = 8Hz, 2Hz,
pyrrole -CH), 5.10 (s, 2H, -CH 2-).
2-Aminomethyl-l-pyrrolylacetic acid (7).8 To a solution of 6 (581 mg, 3.80
mmol, leq) in CH 3OH (12 mL) was added ammonium acetate (2.34 g, 30.4 mmol, 8
eq) followed by sodium cyanoborohydride (191 mg, 3.04 mmol. 0.8 eq). The reaction
was stirred under N2 at room temperature for 18 h, when a precipitate had formed.
The solid was isolated via vacuum filtration. The product was lyophilized
repeatedly to remove excess NH40Ac, and used without further purification. 1H
NMR (250 MHz, D20) 5 6.78 (m, 1H, pyrrole -CH), 6.33 (m, 1H, pyrrole -CH), 6.12 (m,
1H, pyrrole -CH), 4.50 (s, 2H, -CH_2-NH 2), 4.13 (s, 2H, -CH_2-CO 2H). FABMS (m/z):
calc'd for C7H10N20 2, 154.16; found 155 (M+H)+, 177 (M+Na)+.
N-Fmoc-Gly-'[C4N]-Gly-CO 2H (9). To a solution of 7 (0.59 g, 3.25 mmol, 1 eq)
in 10% aqueous Na2CO 3 (12 mL) was added N-(9-fluorenylmethoxycarbonyloxy)
succinimide (1.10 g, 3.45 mmol, 0.9 eq) in dioxane (6 mL), and the reaction was
stirred at ambient temperature for 2 h, when a milky white precipitate had formed.
The mixture was diluted with water and washed 3x with ether. The aqueous layer
was acidified to pH 3 and the product was extracted with ethyl acetate. The organic
layer was dried over MgSO4, filtered, and concentrated in vacuo to provide 360 mg
(0.96 mmol, 25% crude yield) of a white solid. The product was purified by reversed
phase HPLC. Analytical HPLC (C4, 2.0 mL/min): 60/40 H20/CH3CN, (0.1% TFA),
linear gradient to 30/70 (16 min), Rv = 13 mL. Semipreparative HPLC (C4, 15
mL/min): 70/30, linear gradient to 20/80 (16 min), Rv = 170.4 mL. 1H NMR (250
MHz, CDC13) 8 7.75 (d, 2H, J = 9 Hz, Fmoc aromatic -CH), 7.58 (d, 2H, J = 9 Hz, Fmoc
aromatic -CH), 7.40 (d, 2H, J = 9 Hz, Fmoc aromatic -CH), 7.32 (d, 2H, J = 9 Hz, Fmoc
aromatic -CH), 6.54 (m, 1H, pyrrole -CH), 6.11 (m, 2H, pyrrole -CH), 4.62 (m, 2H,
-CH 2-), 4.35 (m, 4H, -CH 2- & Fmoc -CH 2-), 4.20 (m, 1H, Fmoc -CH-). PDMS (m/z):
calc'd for C22H20N20 4, 376.4; found 375.7 (M+H)+.
o-Aminomethylphenylacetic acid 8-lactam (11). Lactam 11 was synthesized by
a published procedure. 7 1H NMR (250 MHz, CDC13) 8 7.28 (m, 2H, aromatic -CH),
7.19 (m, 2H, aromatic -CH), 6.73 (broad s, 1H, -NH-), 4.51 (s, 2H, -CH 2 NH-), 3.59 (s, 2H,
-CH2C(O)NH-).
N-Fmoc-o-Aminomethylphenylacetic acid (13). Amino acid 12 (unprotected)
was synthesized by a published procedure.7 To a solution of 12 (170 mg, 0.846 mmol,
1 eq) in 10% aqueous Na 2 C O 3 (4 mL) was added N-(9-
fluorenylmethoxycarbonyloxy)succinimide (314 mg, 0.93 mmol, 1.1 eq) in dioxane (2
mL). The reaction was diluted with water and washed with ether. The aqueous
layer was acidified to pH 3, extracted with EtOAc, dried over MgSO 4 , filtered and
concentrated in vacuo, to yield 375 mg of a white solid, which was used without
further purification. 1H NMR (250 MHz, DMSO-d 6 ) 8 7.88 (d, 2H, J = 8 Hz, Fmoc
aromatic -CH), 7.78 (dd, 1H, J = 8 Hz, 8Hz, -NH), 7.70 (d, 2H, J = 8 Hz, Fmoc aromatic
-CH), 7.42 (t, 2H, J = 8 Hz, Fmoc aromatic -CH), 7.32 (t, 2H, J = 8 Hz, Fmoc aromatic
-CH), 7.20 (m, 4H, aromatic -CH), 4.32 (d, 2H, J = 7 Hz, Fmoc -CH2-), 4.22 (t, 1H, J = 7
Hz, Fmoc -CH-), 3.65 (s, 2H, -CH_2NH-), 3.34 (s, 2H, -CH_2CO2H).
Synthesis and Characterization of 334-42 Analogs
LMVG-Y[C 4N]G-VVIA (1). Fmoc-Ala was coupled to the HMPB-BHA resin
using diisopropylcarbodiimide (5 eq) and 4-dimethylaminopyridine (DMAP) (0.3 eq)
in DMF for 24 h. Fmoc-VVIA was synthesized using the standard procedure for
Fmoc synthesis. Protected amino acid 9 (1.1 eq) was coupled using 2 eq BOP reagent
and 3 eq DIEA in DMF overnight. The remaining amino acids were coupled using
the standard procedure, and the N-terminus was deprotected prior to cleavage.
Peptide-resin was incubated with 5 mL of 1% TFA/CH 2C12 for 2 min. The reaction
was immediately filtered into 1 mL CH3OH containing 100 gL pyridine to neutralize.
The procedure was repeated until the resin turned pink in color (8 x). The washes
were precipitated into ether to yield a brown solid (49 mg from 429 mg peptide-
resin), and the product was purified by reversed-phase HPLC. Analytical HPLC (C4,
2.0 mL/min): 80/20 H20/CH3CN, (0.1% TFA), linear gradient to 20/80 (20 min), Rv
= 21.8 mL. Semipreparative HPLC (C4, 15 mL/min): 80/20, linear gradient to 20/80
(20 min), Rv = 192 mL. Amino acid analysis: Ala 1.0 (1), Val 2.6 (3), Met 0.7 (1), Ile
0.9 (1), Leu 1.0 (1). PDMS (m/z): calc'd for C42H73N90 9S, 880.2; found, 880.8 (M+H)+.
LMVG-WY[C 6H4]G-VVIA (2). Fmoc-VVIA was synthesized using the standard
Fmoc protocol beginning with Fmoc-Ala coupled to the Wang resin
(Novabiochem). Protected amino acid 13 (1.05 eq) was coupled using 2 eq BOP
reagent and 3 eq DIEA in DMF for 2h. The remaining amino acids were coupled
using the standard procedure, and the N-terminus was deprotected prior to
cleavage. Peptide was removed from the resin using the standard TFA cleavage
procedure, and purified by reversed-phase HPLC. Analytical HPLC (C4 , 2.0
mL/min): 85/15 H 20/CH3CN, (0.1% TFA), linear gradient to 35/65 (16 min), Rv = 26
mL. Preparative HPLC (C4 , 65 mL/min): 95/5 isocratic for 4 min, followed by a
linear gradient to 5/95 (14 min), Rv = 1040 mL. Amino acid analysis: Ala 1.0 (1), Val
2.7 (3), Met 0.8 (1), Ile 0.8 (1), Leu 1.0 (1). PDMS (m/z): calc'd for C44 H 74N 8 0 9S, 891.2;
found, 891.9 (M+H)+.
LMV-[NHPhCO]-VVIA (3) Fmoc-VVIA was synthesized using the standard
Fmoc protocol beginning with Fmoc-Ala coupled to the Wang resin
(Novabiochem). N-Fmoc-p-aminobenzoic acid (synthesized by L. Dong) (3 eq) was
coupled using 3 eq BOP reagent and 3 eq DIEA in DMF for 1.5 h. The remaining
amino acids were coupled using the standard procedure, and the N-terminus was
deprotected prior to cleavage. Peptide was removed from the resin using the
standard TFA cleavage procedure, and purified by reversed-phase HPLC. Analytical
HPLC (C4, 2.0 mL/min): 80/20 H 20/CH3CN, (0.1% TFA), linear gradient to 30/70 (16
min), Rv = 22.6 mL. Semipreparative HPLC (C4, 15 mL/min), 80/20, linear gradient
to 30/70 (20 min), Rv = 204 mL. Amino acid analysis: Ala 1.0 (1), Val 2.1 (3), Met 0.5
(1), Ile 0.7 (1), Leu 1.0 (1). PDMS (m/z): calc'd for C42H 70N 8 0 9 S, 863.13; found, 864.0
(M+H)+.
LMV-[NHPhCH 2 CO]-VVIA (4). Boc-Ala was coupled to the PAM resin using
the standard BOP coupling procedure. Boc-VVIA was synthesized using the
standard procedure for Boc synthesis. N-Fmoc-3-aminophenylacetic acid
(synthesized by L. Dong) (1 eq) was coupled using 2 eq BOP reagent and 3 eq DIEA in
DMF for 1.5 h. The remaining amino acids were coupled using the standard Boc
coupling procedure, and the N-terminus was deprotected prior to cleavage, using
the "low-high" trifluoromethanesulfonic acid (TFMSA) cleavage protocol.22 Low:
Peptide resin (520 mg) was added to a flask under Ar. Dimethylsulfide (1.2 mL), m-
cresol (0.4 mL), TFA (2 mL), and TFMSA (0.4 mL) were added and the reaction was
stirred at 0"C for 2h. The resin was filtered and washed with TFA. The filtrate was
added to cold ether, resulting in precipitation. The pellet was collected by
centrifugation (2000 x g, 10 min), washed 3x with ether, and dried in vacuo to yield
21 mg crude solid. High: To the remaining resin was added thioanisole (0.8 mL),
TFA (5.3 mL), and TFMSA (0.53 mL), and the reaction was stirred for 1 h at 0"C. The
resin was removed by filtration and washed with TFA. The filtrate was precipitated
into cold ether, washed 3x with ether, and dried in vacuo to yield 48 mg crude solid.
Both deprotection steps led to products with similar HPLC traces; the "high" sample
was purified by reversed-phase HPLC. Analytical HPLC (C4, 2.0 mL/min): 80/20
H 20/CH3CN, (0.1% TFA), linear gradient to 15/85 (16 min), Rv = 19 mL.
Semipreparative HPLC (C4, 15 mL/min): 80/20, linear gradient to 30/70 (20 min), Rv
= 179 mL. Amino acid analysis: Ala 1.0 (1), Val 3.1 (3), Met 0.5 (1), Ile 0.9 (1), Leu 0.8
(1). PDMS (m/z): calc'd for C43H72N80 9S, 877.2; found, 877.8 (M+H)+.
LMV-Aib-Aib-VVIA (5). Fmoc-VVIA was synthesized using the standard
Fmoc protocol beginning with Fmoc-Ala coupled to the Wang resin
(Novabiochem). Fmoc-Aib residues were coupled using O-(7-azabenzotriazol-1-yl-)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (3 eq)23 and DIEA (5.3 eq)
in DMF. The remaining amino acids were coupled using the standard procedure,
and the N-terminus was deprotected prior to cleavage. Peptide was removed from
the resin using the standard TFA cleavage procedure, and purified by reversed-
phase HPLC. Analytical HPLC (C4, 2.0 mL/min): 95/5 H20/CH3CN, (0.1% TFA),
linear gradient to 5/95 (15 min), Rv = 29 mL. Semipreparative HPLC (C4, 15
mL/min): 85/15, linear gradient to 5/95 (16 min), Rv = 172.5 mL. Amino acid
analysis: Ala 1.0 (1), Val 2.4 (3), Met 0.7 (1), Ile 0.9 (1), Leu 1.0 (1). PDMS (m/z): calc'd
for C43H79N90 10S, 914.2; found, 915.1 (M+H)+.
LMV-P[CO 2]-GGVVIA (VoG) Boc-Ala was coupled to the hydroxymethyl
(Merrifield) resin using 3 eq of amino acid, 3 eq DIC, and 0.5 eq of DMAP in CH 2C12
for 30 h. Boc-GVVIA was synthesized on using the standard procedure for Boc-
protected amino acids. The N-terminus was deprotected, and bromoacetic acid (3 eq)
was coupled with 3 eq PyBOP and 5.3 eq DIEA. Boc-Val-CO2-Cs + was prepared by
dissolving Boc-Val-CO 2H (1.74 g, 8 mmol, 10 eq) in 16 mL EtOH/H 20 (4:1). The
solution was titrated to pH 7 with 20% CsCO3. The solution was dried in vacuo,
DMF was added, and the suspension was dried in vacuo 2x further. The product
was added to the reaction vessel as a suspension in a minimum volume of DMF,
and the suspension was shaken for 18 h. The resin was washed 2x each with: DMF,
DMF.H 20 (1:1), H20, THF.H 20 (1:1), THF, CH 30H, and CH 2C12. The remaining
amino acids were coupled using the standard procedure, and the N-terminus was
deprotected prior to cleavage. Peptide was removed from the resin using the "low-
high" TFMSA cleavage procedure, 22 and purified by reversed-phase HPLC.
Analytical HPLC (C4, 2.0 mL/min): 85/15 H20/CH3CN, (0.1% TFA), linear gradient
to 20/80 (16 min), Rv = 28 mL. Preparative HPLC (C4, 65 mL/min), 80/20, linear
gradient to 60/40 (18 min), Rv = 249 mL. Amino acid analysis: Gly 1.0 (1), Ala 1.0 (1),
Val 2.3 (3), Met 0.6 (1), Ile 0.9 (1), Leu 0.8 (1). PDMS (m/z): calc'd for C39H70NO011S,
859.1; found, 860.5 (M+H)+.
LMVG-I[CO 2]-GVVIA (GoG) This peptide was synthesized and HPLC purifed
by Dr. B. McGuinness on the PAM resin by a parallel procedure to that described for
VoG. Amino acid analysis: Gly 1.9 (2), Ala 1.0 (1), Val 1.8 (2), Met 0.7 (1), Ile 0.9 (1),
Leu 0.9 (1). PDMS (m/z): calc'd for C39H70N8011S, 859.1; found, 859.8 (M+H)+.
LMVGG-T[C0 2]VVIA (GoV) Boc-Ala was coupled to the Kaiser oxime resin
using DIC (1.5 eq) in CH 2C12 for 24 h. Boc-VIA was synthesized using the standard
procedure, and the N-terminus was deprotected. 2-Hydroxy-3-methylbutyric acid (3
eq) was coupled to the peptide-resin by the standard coupling procedure. Boc-Gly
was coupled to form the depsipeptide linkage using DIC (3 eq) and DMAP (0.5 eq) in
CH 2C12 for 20 h. The remaining amino acids were coupled using the standard
procedure, and the N-terminus was deprotected prior to cleavage. Cleavage was
carried out by addition of solid N-hydroxypiperidine (4 eq) to the resin-bound
peptide in CH 2C12. The suspension was shaken for 12 h at 23"C and filtered to
remove resin. The resin was washed with CH 2C12, DMF, and CH 3OH, and the
filtrate was concentrated. Zn dust (10 eq) and 90% acetic acid (10 mL/g resin) were
added, and the reaction was stirred for 4 h. The Zn was removed by filtration, the
solution was concentrated to remove excess acid, and the peptide was added to H20,
resulting in precipitation. The pellet was collected by centrifugation (2000 x g, 10
min), dried in vacuo, and purifed by reversed-phase HPLC. Analytical HPLC (C4, 2.0
mL/min): 85/15 H20/CH3CN, (0.1% TFA), linear gradient to 15/85 (16 min), Rv =
25.6 mL. Semipreparative HPLC (C4, 15 mL/min), 95/5, 5 min isocratic, followed by
a linear gradient to 5/95 (20 min), Rv = 353 mL. Amino acid analysis: Gly 1.2 (2), Ala
1.0 (1), Val 2.1 (2), Met 0.7 (1), Ile 1.1 (1), Leu 1.0 (1). PDMS (m/z): calc'd for
C39H70N80 11S, 859.1; found, 860.2 (M+H)+.
Aggregation Kinetics
A stock solutions of each f334-42 peptide analog was prepared by dissolving
lyophilized peptide in DMSO. Stock solutions were filtered through Millex FGS 0.2
im filters (for non-aqueous samples), and the peptide concentration was
determined by quantitative amino acid analysis. Prior to each run, an aliquot of
stock solution was diluted to 4.2 mM in 90 giL total DMSO, and added to 910 pgL of
buffer (10 mM sodium phosphate, 100 mM NaC1, pH 7.4), to a final peptide
concentration of 375 gM. The supersaturated solution was stirred at 1550 rpm and
the absorbance at 400 nm was measured every 15 s. Each set of data shown
corresponds to a representative experiment; averaging multiple runs led to
distortion of the data.
Solubility Measurements
Following a kinetic aggregation experiment, the solution was stirred for at
least 24 h and filtered through a Millex-GV 0.22 pm aqueous filter (Millipore).
Quantitative amino acid analysis was used to calculate solubility. Data shown is an
average of at least three separate measurements.
FTIR Spectroscopy
Aggregated peptides were centrifuged at 4000 rpm for 10 min and spread on a
CaF2 plate. After air drying, the infrared spectra were recorded on a Perkin-Elmer
1600 series FTIR spectrometer.
References for Chanter II
1. Olsen, G.L., Bolin, D.R., Bonner, M.P., Bos, M., Cook, C.M., Fry, D.C., Graves, B.J.,
Hatada, M., Hill, D.E., Kahn, M., Madison, V.S., Rusiecki, V.K., Sarabu, R.,
Sepinwall, J., Vincent, G.P. & Voss, M.E. J. Med. Chem 1993, 36, 3039.
2. Giannis, A. & Kolter, T. Angew. Chem. Int. Ed. Engl. 1993, 32, 1244.
3. Spatola, A.F. in Chemistry and Biochemistry of Amino Acids, Peptides, and
Proteins.; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; Vol. VII, pp 267.
4. Wiley, R.A. & Rich, D.A. Med. Res. Rev. 1993, 13, 327.
5. Ibuka, T., Habashita, H., Otaka, A., Fujii, N., Oguchi, Y., Uyehara, T. & Yamamoto,
Y. J. Org. Chem. 1991, 56, 4370.
6. Miles, N.J., Sammes, P.G., Kennewell, P.D. & Westwood, R. J. Chem. Soc. Perkin
Trans. I 1985, 2299.
7. Naito, T., Okumura, J., Kasai, K., Masuko, K., Hoshi, H., Kamachi, H. &
Kawaguchi, H. J. Antibiot. 1977, 30, 698.
8. Abell, A.D., Hoult, D.A. & Jamieson, E.J. Tetrahedron Lett. 1992, 33, 5831.
9. Lansbury, P.T., Jr., Costa, P.R., Griffiths, J.M., Simon, E.J., Auger, M., Halverson,
K.J., Kocisko, D.A., Hendsch, Z.S., Ashburn, T.T., Spencer, R.G.S., Tidor, B. & Griffin,
R.G. Nature Struct. Biol. 1995, 2, 990.
10. Halverson, K., Fraser, P.E., Kirschner, D.A. & Lansbury, P.T., Jr. Biochemistry
1990, 29, 2639.
11. Johnson, R.L. J. Org. Chem. 1987, 52, 2051.
12. Elseviers, M., Van Der Auwera, L., Pepermans, H., Tourwe, D. & Van Binst, G.
Biochem. Biophys. Res. Commun. 1988, 56, 4370.
13. Monzingo, A.F. & Matthews, B.M. Biochemistry 1982, 21, 3390.
14. Sipe, J.D. Annu. Rev. Biochem. 1992, 61, 947.
15. Jarrett, J.T. & Lansbury, P.T., Jr. Cell 1993, 73, 1055.
16. Weinreb, P.H., Jarrett, J.T. & Lansbury, P.T., Jr. J. Am. Chem. Soc. 1994, 116, 10835.
17. Rudinger, J. in Drug Design Vol. II; Ariens, E. J., Ed.; Academic Press: New York,
1971; Vol. pp 319.
18. Roy, J., Gazis, D., Shakman, R. & Schwartz, I.L. Int. J. Pept. Prot. Res. 1982, 20, 35.
19. Blom, C.E. & Giinthard, H.H. Chem. Phys. Lett. 1981, 84, 267.
20. Perricaudet, M. & Pullman, M. Int. J. Pept. Protein Res. 1973, 5, 99.
21. Kaiser, E., Colescott, R.L., Bossinger, C.D. & Cook, P.I. Anal. Biochem. 1970, 34,
595.
22. Stewart, J.M. & Young, J.D. Solid Phase Peptide Synthesis; 1984, Pierce Chemical
Co., Rockford, IL.
23. Carpino, L.A. J. Am. Chem. Soc. 1993, 115, 4397.
Chapter III
Peptide Models of a Hydrophobic Cluster at the C-Terminus of the 1
Amyloid Protein.
There is mounting evidence that production of long AD (primarily i1-42)
may be a pathological event.' In vitro aggregation studies from this laboratory have
demonstrated that long AD nucleates much more rapidly than short AP.2 The
conclusions drawn from these studies were supported by cell culture experiments,
which demonstrated increased production of long AD by APP mutants which
correlate to AD,3 and pathology experiments which implicated deposition of long
AD as a primary event in amyloid plaque formation.4-1  We are interested in
determining the structural and mechanistic basis for the observed differences in
rates of fibril formation. Specifically, we are interested in determining why the
addition of just two amino acids to the C-terminus of AD (i.e. 01-40 to ~31-42) can
have such a dramatic effect on the rate of nucleation.
The development of new methodology has provided a means for the
determination of amyloid structure on a molecular level." As described in Chapter
1, SSNMR and FTIR techniques have demonstrated that 034-42 has an unusual
conformation in fibrils. Initial R2 SSNMR experiments indicated that the
Gly37Gly38 amide bond in this peptide might be in the cis configuration.
Subsequent refinement to the R2 SSNMR has recently suggested that this amide
bond is in fact most likely in the trans configuration. The discrepancy between the
former and latter NMR results stresses the importance of alternative methods to
evaluate the functional significance (in this case, in terms of promoting
amyloidogenesis) of putative structural features. The experiments described in this
chapter are one such method, and were designed to test the feasibility of a cis amide
as an important structural feature for amyloid fibril formation.
Trans to Cis Isomerization may be a Prerequisite for Nucleation.
In order for the A3 amyloid fibril to contain a cis amide bond, this
intrinsically unfavorable structural feature must allow the fibril to assume a
structure which contains a compensating interaction(s). Conversely, if a cis peptide
bond is a requirement for amyloid formation, then structural features which
stabilize the cis amide in solution should accelerate amyloidogenesis. This
reasoning can be incorporated into the kinetic model for AP amyloid formation, as
shown in Figure 3.1. If a cis amide bond is a prerequisite to nucleation, then
stabilization of the cis amide should lead to an increased nucleation rate by
increasing the effective concentration of the aggregating species in solution. By the
nature of the nucleation-dependent polymerization mechanism, the effect of even
very small alterations in KCT will be magnified exponentially (recall that the
nucleation rate is proportional to the concentration raised to the nth power, where
n is the number of molecules in the nucleus).
With Figure 3.1 as a model, one can propose a structural basis for the
increased nucleation rate observed for the longer variants of AP. The amino acids
surrounding a glycylglycine dipeptide moiety will obviously influence the
conformational preference of the peptide, and specifically of the GlyGly amide bond.
If the residues found in 034-42 are particularly effective at stabilizing the cis isomer,
this will provide a driving force for aggregation. The amino acids which distinguish
long AD from short AP (residues 41, 42, and 43) may have the most pronounced
effects on KCT. The resultant differences in the propensity for the cis isomer in
solution would affect the relative rates of nucleation for long Ap and short AP,
perhaps even to the extent observed in in vitro aggregation experiments. 2 To test
this proposal, we have prepared a series of synthetic peptides with a glycylglycine
amide flanked by either the AP sequence or alternate amino acids, and determined
by 1H NMR spectroscopy the effect of these amino acids on the preference of the
glycylglycine amide for the cis isomer in solution. These experiments12 have
allowed us to evaluate the feasibility of a cis amide as a critical structural feature of
the 0 protein aggregate.
Results and Discussion
The Glycine to Sarcosine Replacement Leads to Population of the Cis Isomer.
In a sample of glycylglycine in aqueous buffer, no significant portion of the
cis isomer is detected (<2%, AG > 2 kcal/mol), typical of nonproline peptide bonds in
solution.'3 Even upon addition of valine residues both N- and C-terminally, the cis
isomer is not detected in the 1H NMR spectrum. 4 A difference between the KCT
values for these compounds (for example, 1% vs. 1.25% cis isomer) would not be
measurable. To solve this problem, the Gly37-Gly38 amide bond was replaced with
an N-methylamide (Gly38 = sarcosine, Sar), which affords comparable populations
Icis
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Figure 3.1 Proposed mechanism in which amide isomerization is a prerequisite to
nucleation. If KCT is slow relative to the subsequent intermolecular association
steps, then this equilibrium will dictate the nucleation rate. Small changes in KCT
could have large effects on the rate of fibril formation.
of cis (E) and trans (Z) conformers in solution (Figure 3.2).15 Additionally, the cis
and trans N-methyl groups of sarcosine are well-resolved singlets in the 1H NMR
spectrum, the integration of which provides an accurate measure of the cis/trans
ratio (KCT), which can be used to calculate the free energy (AG) for the isomerization.
The validity of this substitution relies on the assumption that the added N-
methyl group does not interact directly with the flanking sequence. Examination of
models suggests that the Sar N-methyl group cannot directly interact with
neighboring sidechains in a manner that stabilizes the cis conformation. In
addition, NOE difference and ROESY spectra of compound 2 showed no evidence
for an interaction between the N-methyl group and any of the Va136 or Va139
protons. Assuming this to be the case, the ratio of cis to trans amide in the Gly-Sar
peptides should be proportional to the effect on the actual Gly-Gly ratio (e.g. an
increase from 20 to 25% in Gly-Sar would correspond to an increase from 1% to
1.25% in Gly-Gly).
O H O H IH 0
N H2  2•H0 O O
ca. 99%
H3 H 0 O
NH2  NH2
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Figure 3.2 N-methylation leads to population of the cis isomer in solution.
Glycylglycine (upper) has a negligible amount of cis isomer, whereas glycylsarcsosine
(lower) has -22% cis isomer.
The C-Terminal Sequence Stabilizes the Cis Isomer
A series of peptides, based on the 3 protein C-terminus but containing a
sarcosine residue in place of Gly38, were synthesized in order to probe the effect of
the hydrophobic flanking sequence on the amide cis/trans ratio. Peptides were
synthesized as N-acetyl carboxamides in order to most effectively mimic an internal
peptide sequence, and to minimize a possible charge interaction between the N- and
C-termini. The relative percentages of cis and trans isomers were determined to
within 0.4% by integration of the well-resolved N-methyl singlets in the 500 MHz
1H NMR spectrum of a sample in aqueous buffer. The equilibrium constant (KCT)
and the free energy (AG) of isomerization in each case were calculated based on the
percent cis.
Table 3.1 % Cis Amide in p-Amyloid C-Terminal Model Peptides
(X = sarcosine)
peptide
Ac-GX-CONH 2
Ac-VGXV-CONH 2
Ac-VGXVV-CONH 2
Ac-VGXVVI-CONH 2
Ac-MVGXV-CONH 2
Ac-MVGXVV-CONH 2
Ac-EVGXVE-CONH 2
Ac-LEVGXVE-CONH 2
Ac-EVGXVEI-CONH 2
Ac-LEVGXVEI-CONH 2
% cis (±s.d.)
22.3 (±0.37)
25.0 (±0.03)
26.6 (±0.32)
26.6 (±0.32)
25.3 (±0.28)
26.9 (+0.41)
24.9 (+0.14)
24.9 (±0.42)
25.7 (±0.33)
26.4 (±0.31)
KCT
0.29
0.33
0.36
0.36
0.34
0.37
0.33
0.33
0.34
0.36
AG" (kcal/mol)
0.73
0.66
0.61
0.61
0.64
0.59
0.66
0.66
0.63
0.60
Dipeptide 1 (22.3% cis) was considered a control for interactions of the N-
methyl group with the adjacent glycine backbone, and was used as a baseline level to
assess the affect of adding flanking residues. Addition of Val36 and Va139 (1--2) led
to an increase in the amount of cis isomer to 25% (an overall increase of 12%
relative to the control). Addition of Val40 (2-3 and 5--6) increased the amount of
cis isomer by 6%, but addition of Met35 (2--5 and 3--6) had little effect in this
context. No cooperative effect between Met35 and Val40 was observed (e.g. 2-3 =
5--6 and 2-->5 = 3--6).
Hydrophobic Residues Stabilize the Cis Isomer
In addition to AP peptides, a series of model peptides containing alternate
amino acids were synthesized to investigate the importance of hydrophobicity in
determining the cis/trans ratio. In general, increasing the hydrophobicity of the
residues flanking the N-methylamide led to an increased percentage of cis isomer
(Table 3.2). At one extreme, the Ala containing peptide 12 showed no additional
stabilization relative to the GlySar dipeptide 1. At the other extreme, the
tetrapeptide 17 containing phenylalanine, among the most hydrophobic of amino
acids, showed a significant increase in the % cis. Peptide 11, which contains
terminal residues with opposite charges, showed no stabilization of the cis amide,
suggesting that the effect of ionic interactions is minimal.
Table 3.2 % Cis Amide in Hydrophobic Model
peptide % cis (± s.d.)
1 Ac-GX-CONH 2  22.3 (±0.37)
11 Ac-KGXE-CONH 2  22.2 (±0.17)
12 Ac-AGXA-CONH 2  22.6 (+0.33)
13 Ac-AAGXAA-CONH 2 23.9 (+0.13)
14 Ac-AGXV-CONH 2  24.3 (±0.37)
15 Ac-VGXA-CONH 2  24.8 (±0.09)
2 Ac-VGXV-CONH 2  25.0 (±0.03)
16 Ac-IGXI-CONH 2  25.4 (±0.06)
17 Ac-FGXF-CONH 2 33.6 (±0.12)
Peptides (X = sarcosine)
KCT AG (kcal/mol)
0.29 0.73
0.29 0.73
0.29 0.73
0.31 0.69
0.31 0.69
0.33 0.66
0.33 0.66
0.34 0.64
0.51 0.40
This data suggests that the cis amide is stabilized by formation of a
"hydrophobic cluster" involving the adjacent residues. Manual examination of
space-filling models of 2 indicates that, with the amide in the cis configuration,
residues 36 and 39 are able to form a compact, globular structure which minimizes
the exposed hydrophobic surface (Fig. 3.3). Similar hydrophobic clusters have been
implicated in intramolecular protein folding processes. 16 -27 The development of
sensitive NMR methods has permitted the detection of folded structures in short
peptide fragments under conditions where native proteins fold.18 Residual folded
structure due to hydrophobic clustering has been detected in the urea-denatured
states of the 434-repressor 25 and lysozyme.28 These clusters have been postulated to
nucleate the intramolecular process of protein folding. One could imagine that, in
A 3, formation of a hydrophobic cluster serves to nucleate the intermolecular
process of aggregation. The mechanistic implications of cluster formation in
amyloid nucleation are discussed in more detail later in this chapter.
Figure 3.3 (following page) Space-filling models of Ac-Val-Gly-Sar-Val-CONH 2 (2)
with the glycylsarcosine in either the cis (upper) or trans (lower) configuration. The
lower model is depicted as an idealized extended 1-strand. The upper model
illustrates the formation of a hydrophobic cluster involving the valine residues.

Because of the tendency of hydrophobic AD3 peptides to form aggregates, we
considered the possibility that these peptides could be forming soluble oligomers.
Intermolecular interactions could then be responsible for stabilizing the cis isomer
in solution, just as similar intermolecular interactions apparently stabilize the cis
amide in the solid state.29,30 This issue was addressed by recording 1H NMR spectra
at varying concentrations. Peptide 2 showed no concentration-dependence of the 1H
NMR spectrum or of KCT over a range of 3 mM to 27 mM (Table 3.3), indicating that
oligomerization is not responsible for the observed effects.
Table 3.3 Concentration-dependence of KCT in peptide 2.
peptide concentration % cis
2 Ac-VGXV-CONH 2  3mM 24.7
2 Ac-VGXV-CONH 2  10mM 25.0
2 Ac-VGXV-CONH 2  27mM 24.9
Effect of Salt and Denaturant on KCT
The influence of hydrophobic effects on the observed stabilization was
evaluated by recording NMR spectra under different solvent conditions.
Hydrophobic effects should be accentuated in the presence of a high concentration of
salt, and minimized in the presence of denaturant.31 This was found to be the case
(Table 3.4): 1, which lacks the hydrophobic flanking sequence, showed little effect,
but peptides 2 and 3, both of which contain flanking valine residues, show an
increase in KCT in the presence of saturated NaC1, and a decrease in KCT, essentially
to the levels of 1, in the presence of 6M GdmC1. Peptide 7 was affected in a similar
manner, although not as dramatically. These findings support the idea of a
hydrophobic cluster as a stabilizing force for the cis amide isomer.
Table 3.4 Effect of High Concentrations of Salt and Denaturant
on Cis-Trans Equilibrium
% cis
phys. 6M
Peptide buffer sat'd NaCl GdnSCN
1 Ac-GX-CONH 2  22.3 23.3 (±0.26) 22.3 (±0.25)
2 Ac-VGXV-CONH 2  25.0 27.8 (+0.24) 22.7 (±0.95)
3 Ac-VGXVV-CONH 2  26.6 29.1 (±0.17) 23.8 (±0.19)
7 Ac-EVGXVE-CONH 2 24.9 27.1 (±0.15) 25.1 (±0.17)
Temperature Dependence of KcT
The dependence of KCT on temperature was determined for peptides 2 and 6.
With an increase in temperature (over the range 10" to 50"C), a corresponding
increase in % cis was observed in both cases. A van't Hoff plot of InK vs. 1/T
allowed the determination of AH and AS for the isomerization. For peptide 2,
AH(trans-+cis) = +0.325 kcal/mol (±0.1), AS(trans--cis) = -1.1 e.u. (±0.4); for peptide 5,
AH(trans--cis) = +0.327 kcal/mol (+0.1), AS(trans--cis) = -0.8 e.u (±0.4). The positive
enthalpy presumably derives from the relative instability of the cis isomer. The
observed entropy change is difficult to interpret. A negative entropy indicates an
increase in the order in the system. A cursory examination of the data might
suggest that the cis isomer is more ordered than the trans. However, the ordering of
water around the peptide must also be considered; one might actually expect a
positive AS because of the liberation of water molecules from hydrophobic surfaces.
The influence of solvent structure on the thermodynamics, therefore, makes it
difficult to interpret the observed entropy change in terms of the peptide structure.
Table 3.5 Effect of Temperature on Cis-Trans Equilibrium
% cis (± s.d.)
Peptide 100C 25 0C 50"C
2 Ac-VGXV-CONH 2  24.9 (±0.17) 25.0 (±0.09) 26.1 (±0.26)
6 Ac-MVGXVV-CONH 2  27.0 (+0.3) 27.6 (+0.3) 28.3* (+0.3)
* measurement taken at 45"C
One thermodynamic parameter which is considered a hallmark of the
hydrophobic effect is a positive change in heat capacity (ACp>>0). ACp is defined as
the change in reaction enthalpy (AH) with temperature. A positive ACp is observed
upon unfolding of proteins, and is attributed to the ordering of water on exposed,
nonpolar surfaces which are buried in the native conformation. Microcalorimetric
methods have been developed to measure ACp for the folded and unfolded states of
globular proteins. 32 However, in the case of the small, multiconformational
peptides described here, the expected differences in ACp would be infinitesimal, and
would not be expected to provide interpretable information.
An Interaction Between Leu34 and Ile41 Stabilizes the Cis Isomer
We were particularly interested in assessing the effect of the C-terminal
residues which distinguish the long and short variants of AP. Addition of Ile41 to
peptide 3 (3--4) did not affect the cis/trans ratio. This suggested that in order for
Ile41 to participate in a hydrophobic cluster, it may require an interaction with
residues N-terminal to the Gly-Gly amide, and that this residue does not interact
with residues 36, 39, and 40. Addition of Leu34 and Ile41 to the models resulted in
peptides which were not soluble enough to be accurately analyzed. To increase the
solubility of the peptide, Met35 and Val40 were replaced with glutamic acid, and the
incremental change upon addition of Leu34, Ile41, and both residues together was
measured. The increase in % cis upon addition of both residues (7-410 = +6%) was
greater than the sum of the individual contributions (7-48 = +0% and 7-49 = +3%).
Ile41, therefore, may interact with Leu34 in a cooperative manner to stabilize the
putative hydrophobic cluster.
Mechanistic Implications of Hydrophobic Cluster Formation
A model for amyloid fibril formation which incorporates a hydrophobic
cluster is presented in Fig. 3.4. This model suggests the following scenario:
Formation of a hydrophobic cluster stabilizes conformers which contain the cis
isomer in solution. This stabilizing effect leads to a shift in the cis-trans equilibrium
(KCT) toward the cis isomer, effectively increasing the concentration of the
aggregating species in solution, and leading to a corresponding increase in the rate of
nucleation.
K
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Figure 3.4 One possible mechanism for AD amyloid fibril formation. Initial trans to
cis isomerization is slow relative to cluster formation and the subsequent
intermolecular association processes. Therefore, KCT is a critical determinant of the
rate of nucleus formation. The cis amide is stabilized by formation of a hydrophobic
cluster. The side-chain interactions indicated were inferred from the model studies
and may be direct or indirect. They do not necessarily persist in the amyloid fibril.
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This proposed mechanism is consistent with the observed effect of the
residues surrounding the Gly37-Gly38 amide bond in the AP sequence. In
particular, the C-terminal residues which play such a critical role in determining the
rate of amyloid formation 2 may exert their effect by adding stabilization to the
hydrophobic cluster. This increase in the concentration of the aggregating species
could have a dramatic effect on the rate of nucleus formation. Given a nucleus size
of 25, for example, the increase observed for addition of Val40 and Ile41 (~6%) would
lead to a greater than 4-fold 1(1.06)251 acceleration of nucleation, providing one
possible explanation for the measured difference in nucleation times between long
AP and short AP (P26-39, 60 h; P26-40, 12 h; P26-42, <30 sec). The cluster does not
necessarily have to persist in the final amyloid fibril. In fact, SSNMR experiments
have ruled out the presence of a folded hairpin structure centered around the cis
amide bond.29 Instead, the cluster serves to stabilize one key structural feature of the
aggregate.
One assumption implicit to this model is that isomerization is a slow process
relative to the subsequent intermolecular association steps. If isomerization were
rapid, then KCT would be irrelevant to the rate of aggregation; this is an application
of the Curtin-Hammett principle. At the peptide concentration used in our
aggregation assay (40 giM), representative rates of -10 s-1 for interprotein association
(k = 105 - 106 M-ls-1) 33 and ~ 10-2 s-1 for amide isomerization 34 would be expected.
This mechanistic interpretation of the data assumes that the glycylglycine cis
amide is a prerequisite for fibril formation. The discovery that hydrophobic cluster
formation stabilizes the cis amide geometry in solution supports structural models
of the 134-42 fibril which contain a cis amide bond.29,30 Although this was originally
thought to be the case, recent evidence suggests that this bond may actually be in the
trans configuration. 35 If this is the case, then stabilization of the cis amide
configuration will be irrelevant to the rate of fibril formation. However, formation
of a hydrophobic cluster may still accelerate amyloidogenesis by reducing the
entropic barrier to aggregation. In this scenario, the cis-trans ratio in the model
peptides would serve as a indicator of the extent of cluster formation, rather than as
a critical parameter for aggregation.
The observations recorded here may be of interest in the field of protein
folding in a more general sense. Much current interest within this field is focused
on defining the scope of hydrophobic effects, and in particular on elucidating the
specific forces which mediate hydrophobic interactions in protein folding
processes. 36 The observed correlation between hydrophobicity and KCT presented
here suggests that this system may provide a useful method for determining the
strength of specific hydrophobic interactions between two amino acid residues. A
more exhaustive examination of the effect of amino acids with varying degrees of
hydrophobicity might provide useful insight into the conformational features
which influence protein structure.
Experimental Section
Standard Procedures for Peptide Synthesis
Peptides were synthesized on either the 4-methylbenzhydrylamine (MBHA)
resin or the Rink amide resin using either N-Boc or N-Fmoc protected amino acids
and either of the following general procedures. For coupling glycine to sarcosine,
BOP reagent was replaced with an equivalent amount of PyBrOP.37
N-Boc amino acids. (1) Wash resin with CH 2C12 (2x) followed by iPrOH (2x), repeat
3x; (2) remove a small amount of resin and perform the Kaiser test for free amine
(the test should be positive (blue)); (3) wash with DMF (3x); (4) add Boc-amino acid (3
eq, 0.1M in DMF), BOP reagent (3 eq, 0.1M in DMF), and DIEA (5.3 eq), shake resin
for 30 sec, shake mixture for at least 40 min at RT; (5) wash with DMF (3x); (6) wash
with CH 2C12 (2x), iPrOH (2x), CH 2C12 (2x); (7) remove a small amount of resin and
perform the Kaiser test for free amine. If positive (blue) then repeat steps (3) - (7)
until a negative (yellow) result is obtained; (8) add acetic anhydride (10 eq) and DIEA
(5 eq) in CH 2C12, and shake for >20 min; (9) wash with CH 2C12 (3x); (10) add 25%
trifluoroacetic acid (TFA) in CH 2C12 and shake for 30 min. Repeat steps (1) - (10),
ending with deprotection of the N-terminal amino acid. (11) Acetylate the N-
terminal amino acid via steps (6) - (9).
N-Fmoc amino acids. (1) Wash resin with DMF (3x), CH 3OH (3x), CH 2C12 (3x); (2)
remove a small amount of resin and perform the Kaiser test for free amine (the test
should be positive (blue)); (3) wash with DMF (3x); (4) add Fmoc-amino acid (3 eq,
0.1M in DMF), BOP reagent (3 eq, 0.1M in DMF) and DIEA (5.3 eq), shake resin for 30
sec, shake mixture for at least 40 min at RT; (5) wash with DMF (3x); (6) wash with
CH 2C12 (2x), CH 3OH (2x), CH 2C12 (2x); (7) remove a small amount of resin and
perform the Kaiser test for free amine. If positive (blue) then repeat steps (3) - (7)
until a negative (yellow) result is obtained; (8) add acetic anhydride (10 eq) and DIEA
(5 eq) in CH 2C12, and shake for >20 min; (9) wash with CH 2C12 (3x); (10) add 50%
piperidine in DMF and shake for 30-45 min. Repeat steps (1) - (10), ending with
deprotection of the N-terminal amino acid. (11) Acetylate the N-terminal amino
acid via steps (6) - (9).
Standard Procedure for TFMSA Cleavage of Peptide-Resin38
Peptide-resin was placed in a flask under Ar. Thioanisole (2 mL/g resin) was
added, and the flask was cooled to O0C. TFA (20 mL/g) was added, followed after 10
min by trifluoromethanesulfonic acid (TFMSA, 2 mL/g). The reaction was stirred at
0"C for 30 min, then at RT for an additional 2 h. The reaction was filtered to
remove resin, and the resin was washed with a minimum amount of TFA. The
solution was added dropwise to excess cold diethyl ether, resulting in precipitation.
The precipitate was collected by centrifugation (2000 x g, 10 min), washed 3x with
ether, and dried in vacuo.
NMR Methods
Deuterated PBS was prepared by repeated lyophilization of PBS (100 mM
NaCl, 10 mM phosphate, pH 7.4) and reconstitution with D20. NMR samples were
prepared by dissolving - 3 mg of purified, lyophilized peptide in 1 mL of deuterated
buffer. 1H NMR spectra were recorded on a Varian Unity 500 MHz spectrometer.
Cis/trans ratios shown are an average of at least ten separate integrations of the N-
methyl proton singlets.
Synthesis of Sarcosine-Containing Peptides
Unless otherwise noted, peptides were synthesized on the 4-
methylbenzhydrylamine (MBHA) resin using the standard procedures given above,
and characterized by plasma desorption mass spectrometry (PDMS). All peptides
were judged to be >95% pure by analytical HPLC. The synthesis and full
characterization of the following peptides was performed by J. Jarrett, and has been
reported elsewhere:14 Ac-Gly-Sar-CONH 2, Ac-Ala-Gly-Sar-Ala-CONH 2, Ac-Val-Gly-
Sar-Val-CONH2, Ac-Met-Val-Gly-Sar-Val-Val-CONH 2, and Ac-Met-Val-Gly-Sar-Val-
Val-CO 2H.
Ac-AAGSarAA-CONH 2 Ac-Ala-Ala-Gly-Sar-Ala-Ala-CONH 2 was synthesized and
HPLC purified by A. Vaishnav. 1H NMR (100 mM NaC1, 10 mM sodium phosphate,
pH 7.4 in D20) 8 3.95-4.30 (m, 8H, aH), 3.01 (s, 2.3H, Sar trans CH 3), 2.83 (s, 0.7H, Sar
cis CH3), 1.93 (s, 3H, acetyl), 1.24-1.35 (m, 12H, Ala CH 3).
Ac-AGSarV-CONH2 Ac-Ala-Gly-Sar-Val-resin was synthesized and cleaved using
the standard procedures. Analytical HPLC (C4, 2.0mL/min): 100/0 H20/CH3CN,
(0.1% TFA) 10 min isocratic followed by a linear gradient to 50/50 (10 min), Rv = 11
mL. Semipreparative HPLC (C4, 15 mL/min): 100/0 isocratic, Rv = 132 mL. 1H NMR
(100 mM NaCl, 10 mM sodium phosphate, pH 7.4 in D20) 8 3.98-4.31 (m, 6H, zH),
3.06 (s, 2.2H, Sar trans CH 3), 2.88 (s, 0.8H, Sar cis CH 3), 2.06 (m, 1H, Val ~H), 1.98 (s,
3H, acetyl), 1.36 (d, 3H, J = 9 Hz, Ala CH 3), 0.93 (m, 6H, Val CH 3).
Ac-VGSarA-CONH2  Ac-Val-Gly-Sar-Ala-CONH 2 was synthesized and HPLC
purified by A. Vaishnav. 1H NMR (100 mM NaC1, 10 mM sodium phosphate, pH
7.4 in D20) 8 3.95-4.24 (m, 6H, aH), 3.02 (s, 2.2H, Sar trans CH 3), 2.84 (s, 0.8H, Sar cis
CH 3), 2.03 (septet, 1H, J = 7 Hz, Val PH), 1.97 (s, 3H, acetyl), 1.32 (d, 0.8H, J = 7 Hz, cis
Ala CH 3), 1.30 (d, 2.2H, J = 7 Hz, Ala trans CH 3), 0.88 (m, 6H, Val CH3).
Ac-KGSarE-CONH2 Ac-Lys-Gly-Sar-Glu-CONH2 was synthesized and HPLC purified
by A. Vaishnav. 1H NMR (100 mM NaC1, 10 mM sodium phosphate, pH 7.4 in D20)
8 3.91-4.37 (m, 6H, aH), 3.05 (s, 2.2H, Sar trans CH 3), 2.87 (s, 0.8H, Sar cis CH 3), 2.42
(m, 2H, Glu yH), 2.09 (m, 1H, Glu PH), 1.97 (s, 3H, acetyl), 1.93 (m, 1H, Glu PH), 1.80
(m, 1H, Lys PH), 1.69 (m, 1H, Lys PH), 1.63 (m, 2H, Lys 8H), 1.41 (m, 2H, Lys yH).
Ac-FGSarF-CONH2 Ac-Phe-Gly-Sar-Phe-CONH 2 was synthesized and HPLC purified
by A. Vaishnav. 1H NMR (100 mM NaC1, 10 mM sodium phosphate, pH 7.4 in D20)
8 7.2-7.4 (m, 10H, Phe aromatic H), 4.60 (m, 2H, Phe aH), 3.90 (m, 4H, Gly aH), 3.20
(m, 2H, Phe PH), 2.91 (m, 2H, Phe PH), 2.82 (s, 2H, Sar trans CH 3), 2.71 (s, 1H, Sar cis
CH3), 1.94 (s, 1H, cis acetyl), 1.93 (s, 2H, trans acetyl).
Ac-IGSarI-CONH2 Ac-Ile-Gly-Sar-Ile-resin was synthesized and cleaved using the
standard procedures. Analytical HPLC (C4, 2.0 mL/min): 95/5 H20/CH3CN, (0.1%
TFA), linear gradient to 85/15 (20 min), Rv = 27.6 mL. Semipreparative HPLC (C4, 15
mL/min): 90/10, linear gradient to 75/25 (20 min), Rv = 240 mL. 1H NMR (100 mM
NaC1, 10 mM sodium phosphate, pH 7.4 in D20) 8 3.97-4.22 (m, 6H, aH), 3.06 (s, 2.2H,
Sar trans CH3), 2.89 (s, 0.8H, Sar cis CH 3), 2.01 (s, 3H, acetyl), 1.83 (m, 1H, Ile PH), 1.42
(m, 1H, Ile yCH 2), 1.19 (m, 1H, Ile yCH 2), 0.92 (m, 3H, Ile yCH 3), 0.84 (m, 3H, Ile 8CH 3).
Ac-MVGSarV-CONH 2 Ac-Met-Val-Gly-Sar-Val-resin was synthesized using the
standard procedure, and cleaved using the "low-high" TFMSA cleavage.3 8 Low:
Peptide resin (1.1 g) was added to a flask under Ar. Dimethylsulfide (3.3mL), m-
cresol (1.1 mL), TFA (5.5 mL), and TFMSA (1.1 mL) were added and the reaction was
stirred at 0"C for 2h. The resin was filtered and washed with TFA. The filtrate was
added to cold ether, resulting in precipitation. The precipitate was collected by
centrifugation (2000 x g, 10 min), washed 3x with ether, and dried in vacuo. High:
To the remaining resin was added thioanisole (2 mL), TFA (11 mL), and TFMSA (1.1
mL), and the reaction was stirred for 30 min at 0"C. The resin was removed by
filtration and washed with TFA. The filtrate was added to cold ether, resulting in
precipitation. The precipitate was collected by centrifugation (2000 x g, 10 min),
washed 3x with ether, and dried in vacuo. Both deprotection steps led to products
with similar HPLC traces. Analytical HPLC (C4, 2.0 mL/min): 95/5 H20/CH3CN,
(0.1% TFA), linear gradient to 20/80 (16 min), Rv = 22.4 mL. Semipreparative HPLC
(C4, 15 mL/min): 95/5, linear gradient to 20/80 (20 min), Rv = 210 mL. 1H NMR (100
mM NaC1, 10 mM sodium phosphate, pH 7.4 in D20) 8 4.39 (m, 1H, aH), 4.12 (m, 6H,
aH), 3.05 (s, 2.2H, Sar trans CH 3), 2.88 (s, 0.8H, Sar cis CH 3), 2.50 (m, 2H, Met yH), 2.07
(s, 3H, Met SCH 3), 2.06 (m, 4H, Met & Val PH), 1.96 (s, 3H, acetyl), 0.91 (m, 12H, Val
CH 3).
Ac-VGSarVV-CONH 2 Ac-Val-Gly-Sar-Val-Val-resin was synthesized and cleaved
using the standard procedures. Analytical HPLC (C4, 2.0 mL/min): 100/0
H 20/CH3CN, (0.1% TFA), linear gradient to 75/25 (25 min), Rv = 32 mL.
Semipreparative HPLC (C4 Deltaprep, 65 mL/min): 100/0, 6 min isocratic, followed
by a linear gradient to 75/25 (16 min), Rv = 1.53 L. 1H NMR (100 mM NaCl, 10 mM
sodium phosphate, pH 7.4 in D20) 8 3.9-4.2 (m, 7H, aH), 3.00 (s, 2.2H, Sar trans CH 3),
2.83 (s, 0.8H, Sar cis CH3 ), 2.04 (m, 3H, Val PH), 1.97 (s, 3H, acetyl), 0.88 (m, 18H, Val
CH 3).
Ac-VGSarVVI-CONH 2  Ac-Val-Gly-Sar-Val-Val-Ile-resin was synthesized and
cleaved using the standard procedures. Analytical HPLC (C4, 2.0 mL/min): 95/5
H 20/CH3CN, (0.1% TFA), linear gradient to 5/95 (16 min), Rv = 23 mL.
Semipreparative HPLC (C4, 15 mL/min): 100/0, 4 min isocratic followed by a linear
gradient to 30/70 (18 min), Rv = 208.5 mL. 1H NMR (100 mM NaC1, 10 mM sodium
phosphate, pH 7.4 in D20) 8 3.65-4.15 (m, 8H, aH), 3.04 (s, 2.2H, Sar trans CH 3), 2.87 (s,
0.8H, Sar cis CH 3), 2.10 (m, 3H, Val PH), 2.01 (s, 3H, acetyl), 1.80 (m, 1H, Ile PH), 1.49
(m, 1H, Ile YCH 2), 1.23 (m, 1H, Ile YCH 2), 0.81-0.95 (m, 24H, Ile & Val CH 3).
Ac-EVGSarVE-CONH2  Ac-Glu-Val-Gly-Sar-Val-Glu-Rink amide resin was
synthesized according to the standard procedure. The peptide-resin (1.2 g) was added
to a flask under Ar. Ethanedithiol (300 gL, 3%), thioanisole (200 jiL, 2%), and TFA
(9.5 mL, 95%) were added, and the reaction was stirred under Ar for 3 h at RT. The
resin was removed by filtration and washed with TFA. The filtrate was added to
cold ether, resulting in precipitation. The precipitate was collected by centrifugation
(2000 x g, 10 min), washed 3x with ether, and dried in vacuo. Analytical HPLC (C4,
2.0 mL/min): 95/5 H 20/CH3CN, (0.1% TFA), linear gradient to 5/95 (16 min), Rv =
13.2 mL. Semipreparative HPLC (C4, 15 mL/min): 95/5, linear gradient to 5/95 (20
min), Rv = 146.1 mL. 1H NMR (100 mM NaC1, 10 mM sodium phosphate, pH 7.4 in
D20) 8 3.95-4.30 (m, 8H, aH), 3.05 (s, 2.2H, Sar trans CH 3), 2.87 (s, 0.8H, Sar cis CH 3),
2.31 (m, 4H, Glu yH), 2.04 (m, 4H, Glu & Val PH), 1.97 (s, 3H, acetyl), 1.90 (m, 2H, Glu
PH), 0.90 (m, 12H, Val CH 3).
Ac-LEVGSarVE-CONH2 Ac-Leu-Glu-Val-Gly-Sar-Val-Glu-resin was synthesized
and cleaved according to the standard procedures. Analytical HPLC (C4, 2.0
mL/min): 95/5 H20/CH3CN, (0.1% TFA), linear gradient to 70/30 (20 min), Rv = 32
mL. Semipreparative HPLC (C4, 15 mL/min): 95/5, linear gradient to 70/30 (20
min), Rv = 274.5 mL. 1H NMR (100 mM NaC1, 10 mM sodium phosphate, pH 7.4 in
D20) 8 3.98-4.33 (m, 9H, aH), 3.07 (s, 2.2H, Sar trans CH 3), 2.90 (s, 0.8H, Sar cis CH 3),
2.25 (m, 4H, Glu yH), 2.08 (m, 4H, Val & Glu PH), 1.99 (s, 3H, acetyl), 1.92 (m, 2H, Glu
yH), 1.57 (m, 3H, Leu PH & yH), 0.87-0.95 (m, 18H, Val & Leu CH 3).
Ac-EVGSarVEI-CONH2 Ac-Glu-Val-Gly-Sar-Val-Glu-Ile-resin was synthesized and
cleaved according to the standard procedures. Analytical HPLC (C4, 2.0 mL/min):
95/5 H20/CH3CN, (0.1% TFA), linear gradient to 75/25 (20 min), Rv = 36 mL.
Semipreparative HPLC (C4, 15 mL/min): 90/10, linear gradient to 60/40 (18 min), Rv
= 187.5 mL. 1H NMR (100 mM NaCl, 10 mM sodium phosphate, pH 7.4 in D20) 8
3.94-4.30 (m, 9H, aH), 3.04 (s, 2.2H, Sar trans CH 3), 2.88 (s, 0.8H, Sar cis CH 3), 2.20 (m,
4H, Glu yH), 2.06 (m, 4H, Val & Glu PH), 1.96 (s, 3H, acetyl), 1.87 (m, 3H, Ile & Glu
PH), 1.43 (m, 1H, Ile yH), 1.13 (m, 1H, Ile yH), 0.58-0.93 (m, 18H, Ile & Val CH3 ).
Ac-LEVGSarVEI-CONH2  Ac-Leu-Glu-Val-Gly-Sar-Val-Glu-Ile-resin was
synthesized and cleaved according to the standard procedures. Analytical HPLC (C4,
2.0 mL/min): 85/15 H20/CH3CN, (0.1% TFA), linear gradient to 50/50 (16 min), Rv
= 21.6 mL. Semipreparative HPLC (C4, 15 mL/min): 95/5, linear gradient to 5/95 (20
min), Rv = 169.5 mL. 1H NMR (100 mM NaCl, 10 mM sodium phosphate, pH 7.4 in
D20) 8 3.96-4.30 (m, 8H, caH), 3.03 (s, 2.2H, Sar trans CH 3), 2.87 (s, 0.8H, Sar cis CH 3),
2.20 (m, 4H, Glu yH), 2.04 (m, 4H, Val & Glu PH), 1.97 (s, 3H, acetyl), 1.92 (m, 3H, Ile
& Glu PH), 1.54 (m, 3H, Leu PH and Leu yH), 1.43 (m, 1H, Ile yCH 2 ), 1.13 (m, 1H, Ile
TCH 2), 0.79-0.91 (m, 24H, Ile yCH 3, Ile 8CH 3, Val CH 3, Leu CH 3).
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Chapter IV
The Non-An Component of AD Amyloid: A Common Trigger or Target in
Alzheimer's Disease?
Background
In 1993, Ueda et al. identified the "non-Ap component of AD amyloid" (NAC)
as a second intrinsic component of the plaque core, based on its copurification with
AD in the SDS-insoluble fraction of brain homogenate and immunocytochemical
localization to amyloid plaques.1 The minimal 35 amino acid NAC sequence is
shown in Fig. 4.1; the exact length of NAC found in vivo has not been determined.
H2N-EQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATG FV-CO 2H
Figure 4.1 The non-AP component of AD amyloid (NAC).
We noted that the primary sequence of an amino-terminal portion of NAC
(residues 66-73) resembles the amyloidogenic carboxyl terminus of AD (Fig. 4.2).2
This is a critical region of AP: as discussed in Chapter 1, truncated variants of AD,
which form amyloid more slowly in vitro,3 are the primary circulating proteins
while the longer, more rapidly aggregating variants are the primary plaque
proteins.4 A similar sequence is also found in a region of the prion protein (PrP,
residues 117-124, Fig. 4.2). The substitution of Val for Ala at codon 117 of PrP is
found in Gerstmann-Straussler-Scheinker syndrome (GSS).5,6 A peptide containing
this region (PrP106-126) has been shown to form amyloid fibrils and is neurotoxic, 7
suggesting that it is an important region for PrP amyloid formation. These sequence
similarities suggested that specific hydrophobic interactions between NAC (or
NACP), PrP, and AP could occur in vivo.
1 26 4
31-43 DAEFRHDSGYEVI-HHKLVFFAEDVGSNKGA I IGLaM ~GGWIAT
61
NACP GKTKEGV LYVGSKTKEGVVHGVATVAEKTKECWTN VGGAWTG
(31-99)
PrP (82-150) GQPHGGGWGQGGGWHSQCN-PSKPKTNVMKHVAGAA VAGAVGG
95
VTAVAQKTVEGAGSI AAATG FV KKDQ
LGGYM.LGBAMSRPI IH FGSDYE DRYY
A117 V  106 117 126
Figure 4.2 A comparison of sequences from pl-43, NACP, and PrP. Sequence
identities are highlighted. The box indicates the eight-residue hydrophobic region
with local sequence homology. The A117V mutation (*) segregates with the human
prion disease Gerstmann-Straussler-Scheinker syndrome.5,6
Results and Discussion
NAC Peptide Aggregates from Supersaturated Solution to Form Amyloid Fibrils
A 35 amino acid peptide corresponding to the minimal NAC sequence was
synthesized on the solid phase and purified by HPLC. The peptide was characterized
by plasma desorption mass spectrometry, amino acid analysis, and N-terminal
amino acid sequencing. A supersaturated aqueous solution of NAC was prepared
by addition of a concentrated stock solution (in DMSO) to PBS. Aggregation was
monitored by turbidity measurements.3 ,8 The precipitate was isolated by
centrifugation and characterized.
Electron microscopy of NAC showed that it formed unbranched, twisted
fibrils of -50 A in diameter.2 In comparison to 51-40, the NAC fibrils appeared
narrower and often were shorter in length. This observation was confirmed by
using atomic force microscopy to visualize the NAC fibrils, which demonstrated the
same relative morphology (Fig. 4.3). A film of NAC fibrils could be stained with
Congo Red, and, under a polarizing light microscope, exhibited the birefringence
characteristic of amyloid. The Fourier transform infrared (FTIR) spectrum of
fibrillar NAC (Fig. 4.4) was dominated by two low frequency absorption amide I
bands, at 1633 and 1627 cm-1, indicative of antiparallel P-sheet structure.9 These
experiments were the first to demonstrate the ability of purified NAC to form
fibrillar structures which meet the criteria to be called amyloid.10
Figure 4.3 (following page) Atomic force micrographs of NAC and 11-40 amyloid
fibrils. NAC forms unbranched amyloid fibrils (upper). A magnification of an NAC
fibril (lower right, corresponds to the fibril at the top of upper panel) reveals that
NAC is slightly narrower than 31-40 (lower left). Note that the scales on the lower
panels are identical. Similar morphologies are observed using electron microscopy.
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Figure 4.4 Upper trace: FTIR spectrum of NAC amyloid fibrils; lower trace:
Fourier-deconvoluted spectrum. Maxima are at 1633 cm -1 and 1627 cm -1 with a
shoulder at -1690 cm -1, indicative of antiparallel p-sheet structure.
The circular dichroism (CD) spectrum of a sample of saturated soluble NAC
(centrifuged following an aggregation experiment) is shown in Fig. 4.5. This CD
spectrum indicates a high percentage of P-sheet, the characteristic structure of
amyloid fibrils. A similar CD spectrum was observed for aqueous solutions of P10-
43 11 and P1-42.12,13 It is unlikely that NAC is monomeric under these conditions;
310-43 is dimeric in water." Rather, it is probable that the NAC in this sample is a
dimeric or oligomeric P-sheet. Because the solution is stable at equilibrium, any
oligomer present must be smaller than the NAC nucleus. Further investigation
into the size of such "soluble aggregates", for example using dynamic light
scattering, may shed light on the solution conformation of NAC.
Solubility of AD and PrP Peptides in the Presence of NAC
The colocalization of NAC and AP in amyloid plaque could be due to the
formation of highly insoluble coaggregates of these two species. Integrated fibrils
would be expected to have properties which differ from those of the two
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Figure 4.5 CD spectrum of NAC peptide [20 gM peptide in physiological buffer (100
mM NaC1, 10 mM phosphate, pH 7.4)].
homogeneous, or segregated, fibrils.14 To test this hypothesis, we compared the
solubility of each isolated peptide to the solubility of that peptide in the presence of
one other peptide (Table 4.1). Fibrils were prepared by stirring two supersaturated
mixtures, containing one peptide (40 gM) or equimolar in two peptides (40 igM
each). After aggregation, the concentration of each peptide in the soluble phase was
compared using quantitative amino acid analysis. As well as 1-40 and PrP106-126,
we also tested several shortened forms of the AD (P26-40, P26-42, and P26-43) and a
mutant form of the PrP peptide (106-126, Ala117Val).
Table 4.1 Thermodynamic solubilities
of amyloid peptides. 40 iM initial
peptide concentration.
peptide measured solubility (± s.d.)
P26-40 6.2 (1.2)
P26-42 3.4 (0.3)
P26-43 3.1 (0.2)
PrP106-126 15.9 (2.5)
PrP106-126 A117V 8.7 (1.0)
NAC 10.9 (0.8)
The individual measured solubilities in mixtures of AD and PrP-derived
peptides were indistinguishable, within the experimental error, from the solubilities
of the isolated peptides. In contrast, mixtures of NAC with AD or PrP peptides
produced anomalous effects; although the solubility of NAC was not significantly
changed by the presence of other peptides (10.9 ± 0.8 gM), some of the 1 and PrP
peptides showed increased solubility in the presence of 40 giM NAC (Table 4.2). This
phenomenon is not easily interpreted, and an effect on solubility does not
necessarily correlate with the ability to serve as a seed. These experiments revealed
no evidence for the formation of a stable coaggregated species.
Table 4.2 Thermodynamic solubilities of peptide mixtures (40 pM each).
peptide measured peptide measured
1 solubility 2 solubility
026-40 11.8 (1.2) NAC 10.0 (1.1)
026-42 7.2 (0.3) NAC 11.5 (0.7)
P26-43 6.5 (0.5) NAC 8.9 (0.9)
01-40 0.5 (0.1) NAC 11.0 (2.9)
PrP106-126 24.1 (3.0) NAC 12.1 (0.4)
PrP106-126 A117V 16.4 (2.5) NAC 11.5 (0.1)
026-40 9.6 (0.7) PrP106-126 16.5 (7.9)
p26-42 5.1 (0.6) PrP106-126 15.1 (8.4)
P26-43 4.7 (0.3) PrP106-126 16.9 (7.1)
01-40 0.4 (0.1) PrP106-126 20.1 (3.1)
P26-40 9.1 (0.6) PrP106-126 A117V 7.3 (0.2)
J26-42 6.4 (1.5) PrP106-126 A117V 7.8 (2.3)
P26-43 5.1 (2.2) PrP106-126 A117V 5.1 (0.8)
P1-40 0.5 (0.2) PrP106-126 A117V 4.5 (0.3)
NAC Amyloid Formation is Nucleation-Dependent and can be Seeded by NAC
Fibrils
Supersaturated solutions of NAC were metastable. Amyloid formation by
NAC at 80 gtM did not proceed immediately but exhibited a lag time (666 ± 88 min)
characteristic of nucleation-dependent polymerization (Fig. 4.6). This is about 3 to 4
times longer than the lag time observed for 31-40 at the same concentration.3 A
similar mechanism best describes amyloid formation by a number of amyloidogenic
species.3 ,8", 5- 17 One feature of this mechanism is that addition of a preformed fibril
(seed) eliminates the need for nucleation. Thus, addition of NAC fibrils to a
supersaturated NAC solution eliminated the lag time completely, and immediate
seeded growth was observed (Fig. 4.6).
01-40 Amyloid Formation can be Seeded by NAC Fibrils
The rates of amyloid formation from a supersaturated solution of p1-40 (80
giM) in the presence and the absence of NAC seed fibrils (20 jgM) were compared by
monitoring the increase in turbidity (Fig. 4.7). The turbidity due to the presence of
the seed peptide was subtracted from all data points. f1-40 alone exhibited
characteristic nucleation-dependent kinetics of aggregation, with a lag time of -8000
sec. In the presence of NAC, the length of the nucleation phase preceding amyloid
formation decreased by more than 50% (Table 4.3, g). A similar effect was observed
for model peptide 326-40 seeded with NAC (Table 4.3, h). Seeded growth does not
occur immediately, as it does in self-seeding experiments; seeding in this case
manifests itself as a reduction, rather than an elimination, of the observed lag time.
This observation is consistent with the idea that a greater degree of primary
sequence homology leads to more efficient seeding. Seeding is a chemically
discriminating event; small changes in primary sequence can eliminate the ability of
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Figure 4.6 Kinetics of amyloid formation by NAC. *, NAC unseeded (80 RM), 0,
NAC (80 1M) seeded with NAC fibrils (20 gM).
__
a peptide to serve as a seed." This property was demonstrated using peptides
derived from the OsmB proteins and from PrP.'8 The prion peptides showed no
significant ability to seed P26-40 (Table 1, i, j).
In contrast, PrP106-126 and Prp106-126 A117V were not seeded by NAC. In fact,
under certain conditions amyloid formation by the PrP peptides was inhibited by
NAC fibrils. It is possible that soluble NAC formed by disaggregation of the fibril is
responsible for this inhibitory effect. An intriguing corollary to this result is the
observation that addition of NAC fibrils significantly inhibits the conversion of PrPc
to PrPSc in a cell-free system (D. Kocisko, personal communication). Further
exploration of the biochemistry of NAC inhibition of PrP amyloid formation may
therefore be warranted.
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Figure 4.7 Seeding of P1-40 by NAC peptide. *, P1-40 unseeded (80 RM); 0, 01-40 (80
gM) seeded with NAC fibrils (20 IM).
Table 4.3 Nucleation (lag) times measured by turbidity.
Solution Seed Lag time
(80 gM) (20 IM) relative to unseeded*
a NAC p1-40 0.70 (0.02)
b NAC 026-40 0.79 (0.19)
c NAC 126-42 0.47 (0.09)
d NAC 126-43 0.44 (0.14)
e NAC PrP106-126 0.71 (0.22)
f NAC PrP106-126A117V 0.60 (0.12)
g 131-40 NAC 0.4 (0.1)
h 126-40 NAC 0.60 (0.04)
i P26-40 PrP106-126 0.9 (0.2)
j 326-40 PrP106-126A117V 1.1 (0.3)
* Presented as a fraction relative to unseeded lag times [in
min (+S.D.)]: NAC, 666 (88); p1-40, 119 (25); 126-40, 115 (3).
NAC Fibril Formation can be Seeded by B and PrP Peptide Fibrils
The 0 protein analogs shown in Table 4.3 seeded NAC amyloid formation,
albeit less effectively than did NAC itself (Fig. 4.8). Short 0 (01-40 and the model
peptide 326-40), which does not contain the entire homologous sequence, was a less
effective seed than models of long 0 (026-42, 126-43) (Table 4.3, a - d). Addition of
fibrils comprising PrP106-126 and PrP106-126 A117V (a mutation which segregates
with GSS) also led to a decrease in the observed nucleation time (Fig 4.8, Table 4.3 i,
j). No significant difference between the abilities of the Ala- and Val-containing
variants to seed NAC was observed (Table 4.3 e, f). Neither NAC nor 0 was an
effective seed for either PrP analog.
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Figure 4.8 (a) Seeding NAC amyloid formation with Ap. *, NAC unseeded (80 gM);
0, NAC (80 gM) seeded with pl-40 (20 gM); e, NAC (80 gM) seeded with p26-43 (20
gM); 0, NAC (80 gM) seeded with 026-42 (20 jM). (b) Seeding NAC amyloid
formation with PrP peptides. *, NAC unseeded (80 jM); o, NAC (80 gM) seeded
with PrP106-126 (20 jM); o, NAC (80 gM) seeded with PrP106-126 A117V (20 gM).
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NAC May be a Common Trigger or Target in AD
Our experimental data support the theory that NAC, which comprises 10% of
the total protein concentration in the plaque, could promote A3 amyloid formation
in vivo (Fig. 4.9).1,19 One could modify this proposal to suggest that NACP, the
precursor to the NAC peptide, could seed A3 aggregation. While we have observed
no evidence for amyloid formation by NACP (up to millimolar concentrations), a
tendency of recombinant NACP to precipitate has been reported by another
laboratory. 20 If, under physiological conditions, NACP could form fibrils, it could
potentially serve as a seed in a parallel manner as NAC.
Support for the idea of NAC (or NACP) as a "trigger" for AP amyloid
formation comes from subsequent work by Saitoh and coworkers, who confirmed
our finding that synthetic NAC forms amyloid fibrils in vitro,21 and found that
soluble NACP can induce fibril formation by p1-39.22 The conditions used in this
study vary significantly from ours: NACP was used as a soluble factor, which
precludes any seeding phenomenon; and the formation of any insoluble material by
31-39, which is soluble in the absence of NACP, was monitored, rather than
differences in the kinetics of aggregation. Both results, however, point to NAC as a
possible pathogenic "trigger"; production of NAC at high local concentration at the
synapse (via proteolysis of NACP) could seed amyloid formation and have a
neurotoxic effect.
Figure 4.9 (following page) A general mechanism for nucleation-dependent
amyloid fibril formation by Al3 and NAC. A similar mechanism is applicable for
PrP. Heterogeneous seeding was demonstrated to be effective, albeit less effective
than homogeneous seeding.
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An alternative theory is that the promotion of NAC amyloid formation by P
or prion proteins could be pathogenic (Fig. 4.9). We find that peptides derived from
both AP and PrP sequences exhibited the ability to seed NAC amyloid formation in
our in vitro assay. The 'long 0' models, which have a greater sequence homology to
NAC, were more efficient seeds, once again supporting the importance of the
sequence homology. Thus, aggregation of NAC itself, or the synaptic precursor
protein NACP, may be promoted by other amyloid proteins in vivo.
This possibility leads back to the role of NACP/a-synuclein, the synaptic
protein from which NACP is derived. Although the function of NACP is
unknown, it is found primarily in brain tissue,2 3 and is localized within neurons at
the presynaptic nerve terminal.23-25 Synaptic amyloid deposition may be a common
theme among amyloid-characterized neurodegenerative disorders.23 This premise
inspired further biochemical studies, described in the next chapter, designed to
investigate the structure and function of NACP.
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Experimental Section
Peptide Synthesis. Purification, and Characterization
NAC was synthesized and purified by Dr. Hogyu Han using the standard
Fmoc protocol (Chapter II) on the Wang resin. Analytical HPLC (C4, 2.0 mL/min):
70/30 H 20/CH3CN (0.1% TFA) isocratic (Rv = 18 mL). Amino acid analysis (from a
DMSO solution): Asx 0.6 (1), Glx 3.0 (4), Ser 1.0 (1), Gly 5.5 (6), Thr 3.9 (5), Ala 7.0 (7),
Val 5.7 (8), Ile 1.1 (1), Phe 1.1 (1), Lys 0.9 (1). N-terminal amino acid sequencing (MIT
Biopolymers Laboratory) of the first 26 residues of the peptide was consistent with
the expected sequence; a trace amount (0.5% to 1%) of an impurity beginning at
Ala16 of the NAC sequence was also detected. PDMS (M + H+): calc'd 3262.7, found
3258.4.
Peptides P26-40, f26-42, P26-43, PrP106-126, and PrP106-126 A117V were
prepared by methods reported previously. 14,16 01-40 was purchased from Bachem
(Torrance, CA). Stock solutions were prepared by dissolving lyophilized peptides in
DMSO. The solutions were filtered through Millex FGS 0.2 gim non-aqueous filters,
and concentrations were determined by quantitative amino acid analysis.
Electron Microscopy, Atomic Force Microscopy, and Congo Red Staining
Samples for EM were prepared by stirring supersaturated solutions of peptide
(80 gIM) in 100 mM NaC1/8.2 mM Na2HPO 4 /1.8 mM NaH 2PO 4, pH 7.4/10%
dimethylsulfoxide (PBS/10% DMSO). EM samples were placed upon carbon-coated
copper grids, negatively stained with 2% uranyl acetate, and viewed at 60K-120K on
a JEOL 1200 CX EM at 80 kV.
CR staining was performed by the following procedure:8 A suspension of
peptide fibrils in buffer was dried on a glass microscope slide. The peptide was
immersed in a solution containing 1 mM Congo Red, 100 mM NaCl, and 10 mM
104
phosphate (pH 7.4) for 1 min and dried. Birefringence was determined with a Wild
Leitz M3Z light microscope equipped with a polarizing stage.
Atomic force microscopy was performed with the assistance of James Harper.
A suspension of aggregated NAC (initial concentration, 80 gM) was prepared as
described in "Aggregation Kinetics." A portion of this suspension (20 RL) was placed
onto a piece of freshly cleaved mica. The sample was incubated for 1 h at RT with
high humidity and was rinsed 2 x 50 jgL with ddH20 to remove unbound material.
The sample was imaged immediately under ambient conditions using a NanoScope
IIIa MultiMode scanning probe workstation (Digital Instruments, Santa Barbara, CA)
operating in the TappingModeTM, using an "E"-type scanner and etched silicon
TESP nanoprobes (Digital Instruments).
Circular Dichroism Spectroscopy
Following an aggregation experiment, a suspension of NAC was centrifuged
to remove large aggregates, and filtered through a Millex-GV 0.22 jim aqueous filter
(Millipore). Spectra were recorded on a Jasco J-500 Spectropolarimeter, in a 0.1 cm
quartz cell. The following parameters were used: Band width = 1.0 nm; slit width =
"auto"; time constant = 16 sec; step resolution = 0.4 nm; scan speed = 10 nm/min.
FTIR spectroscopy
Aggregated peptides were centrifuged at 4000 rpm for 10 min and spread on a
CaF2 plate. After air drying, the infrared spectra were recorded on a Perkin-Elmer
1600 series FTIR spectrometer.
Solubility
A supersaturated solution of peptide (40 jgM) or a mixture of two peptides (40
giM each) in PBS/10% DMSO was prepared by addition of 20 gL of a DMSO solution
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of peptide to 180 gL of PBS, and stirred at 1800 rpm for 72 h. The suspension was
filtered through a Millex-GV 0.22-gm aqueous filter (Millipore). Total peptide
concentrations were determined by quantitative amino acid analysis (MIT
Biopolymers Laboratory), and the relative ratios were determined based on
unshared amino acids. Data shown represent an average of three trials.
Aggregation Kinetics and Seeding Experiments
A supersaturated solution of peptide (80 jgM) in standard buffer was prepared
by addition of peptide dissolved in DMSO (100 jgL; 50 ptL for 31-40 and 026-40) to PBS
(900 giL; 450 pgL for 31-40 and 026-40) and stirred continuously at 1800 rpm (1550 rpm
for 31-40 and 026-40). Samples were vortexed briefly (except for 31-40 and 126-40)
and aggregation was measured by turbidity at 400 nm versus a buffer blank. Seeding
experiments were initiated by addition of a suspension of fibrils (250 gL; 125 gL for
seeding 31-40 and 126-40; 20 gM final) from a previous aggregation trial. The
turbidity due to the seed peptide was accounted for by blanking on the suspension of
seeds in buffer immediately before addition of the DMSO stock solution. Lag times
were determined by solving the best fit line to the growth phase of the aggregation
curve for y = 0.
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Chapter V
Biochemical Probes of NACP Structure and Function: Interaction of
NACP, a "Natively Denatured" Protein, with the NSF Homolog VCP (p97)
Background
The NACP/Synuclein Family of Proteins
NAC was identified in 1993 as an intrinsic component of AD amyloid plaque.1
The gene encoding the protein precursor to NAC was cloned, and the protein was
named "NACP". The human NACP gene is on chromosome 42-4 and encodes a
highly acidic 140 amino acid protein with a predicted molecular weight of 14,460
(Fig. 5.1, 5.2). NACP isolated from human brain tissue has a molecular mass of
14,681, suggesting that NACP may be post-translationally modified.5 The N-
terminal amino acid of isolated NACP is not amenable to Edman degradation,5
suggesting that this modification may occur at the amino terminus. There are no
consensus glycosylation sites, signal sequences, or phosphorylation motifs in the
NACP sequence. However, a homolog of NACP (PNP-14) is phosphorylated in
vitro.6 Cysteine, arginine, and tryptophan residues are all noticeably absent from the
NACP sequence.
NACP, also called a-synuclein, is a member of a highly conserved family of
proteins encoded by equivalent genes in a number of different species. This family
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Figure 5.1 A schematic of the NACP sequence, showing three distinct regions. The
N-terminal repeat region is conserved among all members of the
NACP/synuclein/synelfin/PNP family and bears some similarity to the
amphipathic helices of apoE.7 The central hydrophobic region, which is excised to
produce the amyloid peptide NAC, is partly conserved (NACP60-72 and 86-95) in 1-
synuclein/PNP14. The acidic C-terminal region is not conserved among family
members and the 103-130 sequence is removed in an alternatively spliced form.8
includes Torpedo synuclein,9 rat synucleins 1, 2, and 3,10 bovine phospho-
neuroprotein 14,6,11-13 canary synelfin,7 and human P-synuclein5 (Fig. 5.2). There are
two major isoforms in this family, which differ in their C-terminal amino acid
composition. NACP (a-synuclein), rat synuclein 1, and canary synelfin share the
same acidic C-terminus. These proteins can be considered interspecies homologs;
that is, proteins with equivalent functions in different species. Human and rat
NACP share ca. 95% sequence homology,14 while canary NACP (synelfin) is ca. 85%
homologous to both sequences.7 The second set of isoforms includes bovine PNP-14
and the human homolog 3-synuclein, which do not contain the intact NAC
sequence. An alternatively spliced form of human NACP (NACP112) has been
discovered 8 which lacks amino acids 103 to 130, but contains the intact NAC
sequence.
The N-terminal sequence is highly conserved among all members of the
NACP/synuclein/synelfin/PNP-14 family. This sequence is composed almost
entirely of variants of an 11 amino acid consensus motif. This type of motif has also
been described in the exchangeable apolipoproteins (AI, AII, AIV, CI, CII, CIII, and E).
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Figure 5.2 Sequences of NACP in various species. Amino acids that differ from the
human NACP sequence are indicated.
The apolipoproteins have a-helical structures, and the 11 residue repeat has been
suggested to provide an amphipathic motif responsible for lipid binding.15 Helical
wheel analysis indicates that the NACP amino terminal sequence (residues 9-26)
also shows clear segregation of polar and nonpolar residues on opposite faces of the
predicted helix.7 Furthermore, as in the apolipoproteins, there is a basic residue at
each polar-apolar interface; such residues have been proposed to be responsible for a
"snorkeling" effect to maximize lipid binding. 16 Direct NACP binding to lipid,
therefore, may be responsible for its observed association with membranes (vide
infra). Alternatively this amphipathic helix may mediate interactions of NACP
with other proteins. Specifically, the similarity to apoE suggests that this region may
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mediate interactions between NACP and AP; apoE has been shown to bind AD in
vivo17-19and alter the kinetics of amyloid fibril formation in vitro. 20
Other NACP Homologies
In addition to the strong resemblance of the N-terminus of NACP to the
amphipathic helix of the apolipoproteins, some other possible sequence homologies
have been noted, which may provide valuable clues as to the function of NACP.
The KTKEGV sequence, which is a part of the conserved 11 amino acid repeat, is
found in the carboxy terminal portion of the rho gene product, a protein implicated
in signal transduction,9 and in the low molecular weight heat shock protein HS27.10
A possible tyrosine phosphorylation consensus sequence (KTKEGVLY) is found at
the end of the third repeat,1' and the threonine residue in the KTKEGV may
constitute a favorable protein kinase C target.' Clusters of acidic and basic amino
acids, such as in the KTKEGV repeat sequence, are known to mediate binding
between structural proteins.5
The C-terminus of NACP showed limited homology to the calmodulin
dependent-kinase, type II, and is somewhat reminiscent of the YGP/QQG repeat of
the synaptophysin tail.1' This region also bears some homology to the CD3ý subunit
of the T-cell antigen receptor.8 The C-terminus of P-synuclein contains a conserved
motif found at the beginning of the coil region of the intermediate filament and in
the clathrin light chain.'0
NACP is a Presynaptic Protein
The tissue distribution and intracellular localization of the NACP/synuclein
family of proteins has been studied extensively. Scheller and colleagues used an
antiserum against cholinergic synaptic vesicles in their initial discovery of a-
synuclein in Torpedo and rat.9 The synuclein gene was shown to be expressed only
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in neurons, and immunoreactivity was localized to a region of the nucleus as well
as the presynaptic nerve terminal (hence the name, "synuclein"). Using in situ
hybridization in rat brain tissue, the same group later demonstrated very high levels
of synuclein expression in cerebral cortex, hippocampus, and dentate gyrus, and
showed that the protein is reversibly associated with synaptosomal membranes.'0 A
similar tissue distribution and intracellular localization was observed for human
NACP (ca-synuclein).5 Immunochemical studies with an affinity purified NACP
antibody suggested that the protein is localized only to the synapse, and not to nuclei
as proposed previously. 21 The immunoreactivity in the synapse was associated with
synaptic vesicles; however, as the protein was recovered primarily in cytosolic
fractions, it was postulated to be only loosely associated with the membrane or with
membrane binding proteins.21 This antibody was also used to confirm preferential
NACP expression in the hippocampus, striatum, frontal cortex, and olfactory bulb.
0-synuclein, similarly, is expressed predominantly in brain, and associates with
synaptosomal fractions, but not with purified synaptic vesicles.13 Differences in the
intracellular distribution of human a and P synuclein have been suggested by
immunochemical studies.5 The alternatively spliced NACP transcript NACP112
shows a different tissue distribution from NACP, suggesting tissue-dependent
alternative splicing. 8
The conclusions from these studies are as follows. The synuclein family of
proteins is predominantly expressed in brain tissue, and specifically in the regions of
the brain which are most affected by AD. The proteins are reversibly associated with
synaptosomal membranes and synaptic vesicles. Within neuronal cells, NACP and
homologs are specifically localized to the presynaptic nerve terminal. This
convergence of evidence suggested that NACP may play a role in synaptic
transmission.
112
Canary NACP (Synelfin) is Upregulated During Songbird Learning
Perhaps the most exciting clue as to the function of NACP came from a
seemingly unrelated research project. A group led by David Clayton, at the
University of Illinois, was studying the molecular mechanisms which control
songbird learning. Using differential hybridization techniques, this group identified
a gene which is a target of dynamic regulation during the critical period for song
learning. The gene was cloned and sequenced, and was found to encode a protein,
dubbed "synelfin," which is the canary homolog of NACP (Canary NACP and rat
NACP share ca. 85% sequence identity).7 It was suggested that synelfin is responsible
for regulating "synaptic plasticity"; that is, in establishing and maintaining synaptic
interconnections. This report provided a link between NACP expression and
learning/memory, and raised the possibility of a broader connection between AD
and the regulation of neural plasticity.
An NACP Promoter Polymorphism Correlates to AD
Recent attempts have been made to discover a direct link between NACP and
AD. Analysis of the NACP/synuclein gene in a group of 26 patients with familial
AD revealed no mutations in the coding sequence.3 However, a mutation in the
promoter region of the NACP gene has been shown to correlate to disease.22
Additionally, NACP concentrations in various regions of the brain were slightly
altered in AD. 23 This results provide the first evidence for a link between NACP
expression and Alzheimer's disease.
NACP: A Genetic Connection Between Learning and AD?
NACP, a presynaptic protein associated with synaptic vesicles, is expressed
primarily in the regions of the brain which are most affected by AD. A fragment of
NACP is deposited in AD amyloid plaques. NACP expression, which is regulated
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during a critical period for songbird learning, is altered in AD. Taken together, these
findings suggest that NACP may play a role in connecting the processes of AD and
learning. The molecular basis for this connection, however, remains unclear. The
results presented in this chapter describe the use of biochemical methods to
elucidate the molecular details of NACP structure and function, and suggest a
molecular connection between learning and AD.
Results and Discussion
Structural Studies of Recombinant NACP
Expression and Purification of Recombinant NACP
A pRK172 plasmid encoding the human a-synuclein sequence (kindly
provided by R. Jakes and M. Goedert, MRC) was used to transfect E coli BL21(DE3)
cells.5 Bacteria were grown and induced with isopropyl-l-thio-~-galactoside as
described in the Experimental Section. The soluble fraction of the cell lysate was
treated with streptomycin sulfate to precipitate nucleic acids. NACP was purified by
boiling the cell homogenate for 10 min, which precipitates most cellular proteins,
leaving NACP as the major component of the soluble fraction. Final purification of
NACP was accomplished using size-exclusion chromatography. The protein eluted
from a Biogel P-10 column in the void volume, but was deemed sufficiently pure to
use in structural studies by SDS-PAGE and analytical reversed-phase HPLC.
Subsequent purifications have utilized a Sephacryl S-300 column to achieve greater
purity (W. Zhen, unpublished results). NACP elutes from an S-300 column with an
apparent Mr of -55 kDa relative to globular protein standards, suggesting an
elongated or oligomeric structure (vide infra).
This purification procedure takes advantage of the heat-stability of a-
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synuclein. We were concerned that, although it does not lead to precipitation,
boiling of the protein could lead to loss of the native folded structure. We therefore
developed a milder, conventional purification of recombinant NACP which did not
involve boiling (Fig 5.3).24 Following the streptomycin sulfate precipitation, NACP
was precipitated using 47% ammonium sulfate. The precipitate was further purified
using size-exclusion and ion-exchange chromatography. This purification method
should retain the native folded structure, if any, of NACP.
Recombinant NACP was characterized by several independent methods.
MALDI-TOF mass spectrometry confirmed the predicted mass of 14,461, and amino
acid analysis was consistent with the expected sequence. Proteolytic digestion with
trypsin followed by plasma desorption mass spectrometry (PDMS) of the resultant
peptide mixture led to the positive identification of several NACP fragments.
Finally, Western blotting of recombinant NACP with a monoclonal antibody to
canary synelfin7 confirmed NACP immunoreactivity.24
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Figure 5.3 Parallel methods for the purification of recombinant NACP. Scheme (a)
involves the use of a boiling step, and may not retain the native protein structure.
Scheme (b) utilizes conventional purification methods which retain native
structure.
Secondary Structure Prediction
Analysis of the predicted secondary structure of NACP was performed using
the classical Chou-Fasman algorithm (kindly performed by Dr. G.D. Fasman,
Brandeis University).25 Predictions such as this can often be helpful in locating well-
defined structural motifs and providing an initial sense of protein structure,
although by no means should such predictions be equated with experimental
methods for structure determination. The result is shown in Fig. 5.4. The N-
terminus of NACP is predicted to be largely a-helical, particularly a stretch between
amino acids 9 and 32. This is consistent with helical wheel analysis (see Background
section), which suggests an amphipathic helix motif. The hydrophobic center of the
protein, which contains the NAC sequence, is predicted to have primarily P
structure. The C-terminus is predicted to have a heterogeneous structure; however,
the preference is not particularly strong in this portion of the molecule for any of
the possible structural types.
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Figure 5.4 Secondary structure prediction of NACP, using the Chou-Fasman
algorithm. 25 "a" = a-helix; "0" = 1-sheet, "5t" = 3-turn. The NAC sequence is
underlined.
NACP is Monomeric in Solution
Recombinant NACP exhibited unusual mobilities on both SDS-PAGE and
size-exclusion chromatography. NACP, with a molecular weight of 14.4 kDa, runs
as an Mr~19kDa protein on denaturing gel electrophoresis. This effect has been
reported previously,5 and may be attributed to abnormally low binding of SDS by the
highly acidic NACP C-terminal sequence. A similar effect has been reported for
other highly acidic proteins.26
Upon size exclusion chromatography, NACP elutes in the void volume of
both Biogel P-10 and P-100 columns. On a Sephacryl S-300 column, the protein
elutes with an apparent molecular weight of -55 kDa, relative to globular protein
standards. P~-Synuclein reportedly exhibited a similar mobility (Mr -56 kDa).11 This
was interpreted to mean that the protein exists as a tetramer in solution. However,
an alternative explanation is possible: Elongated, non-globular structures have been
reported to exhibit unusually high Stokes' radii relative to compact, globular
proteins. We used native gel electrophoresis to clarify whether NACP is oligomeric
or monomeric in solution.
Recombinant NACP and several globular protein standards were run on
three different percentage non-dissociating ("native") polyacrylamide gels (6%, 10%,
and 14%). A plot of the relative mobility (Rf) of each species versus the gel
concentration (% acrylamide) (Ferguson plot27) was used to calculate retardation
coefficients (Fig. 5.6). The slope of the Ferguson plot is defined as Kr, the retardation
coefficient. Since the Ferguson plot relates to mobility during electrophoresis when
only the gel pore size (as determined by % acrylamide) is varying, then Kr is a
measure of the retardation of the protein by the gel, and is directly related to
molecular size. A plot of Kr vs. molecular weight allows the estimation of a
molecular weight of -20 kD for NACP. (Fig. 5.5) This clearly corresponds to a
monomer. It is likely that this type of analysis would reveal a similar monomeric
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nature for P-synuclein, as opposed to the reported tetramer.11 This analysis, along
with CD and UV denaturation experiments and urea gel-shift experiments (vide
infra) confirms that NACP is clearly monomeric in solution.
Circular Dichroism Indicates NACP is Predominantly Random Coil
With recombinant NACP in hand, we initially chose to examine the structure
of the protein using circular dichroism (CD) spectroscopy. CD is a useful tool for
determining the dominant secondary structural elements for a given protein. The
CD spectrum of NACP purified by boiling (20 giM in PBS, Fig. 5.6) has a negative
ellipticity at -200 nm, and is characteristic of random coil structure. The method of
Greenfield and Fasman 28 was used to estimate the relative abundance of each
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Figure 5.5 Determination of NACP molecular weight by non-dissociating
polyacrylamide gel electrophoresis. A retardation coefficient (Kr) was calculated for
each protein, based on relative mobilities in gels with different percentages of
acrylamide. A plot of Kr vs. molecular weight indicates NACP is monomeric.
secondary structural element (Table 5.1). This method is fairly effective at
calculating helix content; the 1-sheet content obtained using these calculations is
much less reliable. Using this method, NACP is calculated to have only about 2%
helical structure, with the remainder primarily random coil.
190 200 210 220 230 240
Wavelength
Figure 5.6 CD spectrum of NACP. The negative ellipticity at about 200 nm is
characteristic of "random coil" structure. 29 A similar spectrum has been observed
for denatured proteins.
Table 5.1 Calculated percentages of secondary structural elements
in NACP under varying conditions.
[NACP] (jgM) conditions % a % p % coil
10 heat-treated 4 29 67
20 " 2 30 68
40 " 2 29 69
60 " 1 31 68
80 " 1 32 67
20 "native" 2 30 68
20 10% (v/v) HFIP 52 1 47
10 mM SDS 27 13 60
10 mM CaC12  0 33 67
120 gM ATP 1 28 71
pH 4.5 2 30 68
" pH 10 2 30 68
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The material used in these initial CD studies was purified using a heat
treatment step. We hypothesized that the apparent lack of structure observed in the
NACP CD spectrum was due to denaturation of the protein by the boiling step. The
experiment was repeated, this time with a sample of NACP which had been purified
by conventional methods designed to retain native protein structure. The CD
spectrum of this preparation was identical to that of the boiled sample (Fig. 5.7).
This was confirmed by boiling the "native" CD sample, which led to an identical CD
profile. Thus, the heat treatment step does not appear to affect the structure of the
protein, and may be safe to use in future NACP purification schemes.
We investigated the possibility that oligomerization of NACP could induce
secondary structure, by monitoring the concentration dependence of the CD
spectrum. Over a range of 10 jiM to 620 jgM, the spectrum was independent of
concentration. This indicated that NACP is monomeric over this concentration
range.
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Figure 5.7 CD spectra of "boiled" (solid line) and "native" (dashed line) NACP.
We next considered the possibility that exogenous or endogenous molecules
could induce structure in NACP. Addition of 10-20% hexafluoroisopropanol (HFIP)
induced a-helical structure (52%). This was expected based on the documented
ability of HFIP to promote helical structure.30 Addition of SDS micelles (10 mM)
also induced helical structure, though not as effectively as HFIP (Figure 5.8). This
effect is not as straightforward to interpret. SDS has been shown in some cases to
increase helical structure, presumably by providing a less polar solvent
environment, and in other cases to decrease helical structure, due to denaturation
effects.31  The effect of SDS in this case may be attributed to a direct binding
interaction between the amphipathic helix of NACP and the SDS micelle.
Other potential mediators of structure had no effect on the CD of NACP. The
spectrum was independent of pH over a range of 4.5 to 10. Addition of Ca2+ ions (10
mM CaC12), at both pH 4.5 and 7, had no measurable effect, nor did addition of ATP,
another ubiquitous intracellular species. A CD spectrum such as that observed for
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Figure 5.8 CD spectrum of NACP in buffer (solid line), with 10% HFIP (dotted line),
and with 10 mM SDS (dashed line).
NACP does not in and of itself preclude the presence of any folded protein structure.
For example, the spectrum of the polyproline II helix is very similar to the classical
random coil spectrum, despite the highly ordered structure of the molecule.32 It
would therefore be unwise to conclude that NACP is unstructured solely on the
basis of a "random coil" CD spectrum. To clarify this issue, we performed several
independent methods of structural characterization which confirm the
unstructured nature of NACP.
Fourier Transform Infrared (FTIR) Spectroscopy of NACP
In addition to its traditional use in characterizing functional groups in
organic molecules, infrared spectroscopy can be used to determine secondary
structures in proteins. The position of the amide I band of proteins, specifically, is
indicative of the predominant type of secondary structure. a-Helix generally shows
an absorbance in the range of 1658-1650 cm-1; n-sheet absorbs at 1695-1690 cm -1, and
random coil proteins generally absorb near 1648 cm-1. 3 3,34 The FTIR solution
spectrum of NACP in buffer (Fig. 5.9) shows a broad absorbance at 1642 cm -1,
characteristic of a denatured or random coil protein.
Non-Dissociating Gel Electrophoresis and UV Spectroscopy of NACP in Denaturants
The UV absorption spectrum of an aromatic amino acid depends on the
nature of the molecular neighborhood of the chromophore. In folded proteins,
some of the aromatic amino acids are buried within the hydrophobic core of the
molecule. Denaturation of a globular protein leads to exposure of amino acids to a
more polar aqueous environment. This, in turn, leads to a shift in the wavelength
of the aromatic amino acids to a lower wavelength (blue shift). Such shifts are
generally small, but can easily be detected using difference spectroscopy.35 The
spectrum of NACP in the presence and absence of 6 M guanidine hydrochloride
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Figure 5.9 FTIR solution spectrum of NACP. Maximum absorbance is at 1642
cm-1, indicative of random coil.
(GdmC1) was measured (Fig. 5.10). The difference spectrum (folded - unfolded)
shows no significant peaks in the 285-288 nm range, where differences in tyrosine
residue environment would be detected. NACP contains 4 tyrosine residues, 3 of
which are in the acidic C-terminus. This experiment indicates that these residues
are not buried within a folded, hydrophobic core, consistent with the idea of a
protein with minimal folded structure.
A parallel experiment was performed by examining the aromatic contribution
to the CD spectrum (W. Zhen, unpublished results). As in the UV experiment,
changes in the environment of the aromatic residues should be detectable in the
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Fig. 5.10 UV spectra of "native" (dotted line) and "denatured" (dashed line) NACP.
The spectrum of NACP in 6M guanidine hydrochloride was subtracted from the
spectrum of NACP in buffer to obtain the difference spectrum (solid line). The
absence of a peak at -280 nm in the difference spectrum is consistent with a lack of
buried aromatic residues.
"folded - unfolded" difference spectrum. No significant peaks were detected in the
aromatic region of the CD difference spectrum of NACP.
Addition of denaturants to the sample loading buffer has been shown to alter
the mobility of globular proteins on non-dissociating ("native") polyacrylamide gel
electrophoresis.3 6 Addition of saturated urea to a sample of NACP did not affect the
mobility of the protein. This confirms both the monomeric nature of NACP and
the lack of any significant folded structure.
NACP May Define a Family of Natively Denatured Proteins
The results presented in the preceding sections provide overwhelming
evidence that, in solution, NACP is a monomer with no detectable folded structure.
The monomeric nature of NACP was demonstrated by Ferguson analysis, and is
consistent with a concentration-independent CD spectrum and a native gel mobility
which is unaltered in the presence of urea. The random coil nature of the protein
was demonstrated by CD, FTIR, UV, and native gel electrophoresis, as well as an
unusually high Stokes' radius on size-exclusion chromatography.
These features allow us to characterize NACP as a "natively denatured"
protein. This term was coined by Mandelkow and coworkers37 to describe another
AD-related protein, tau, and can be defined as a protein which, under physiological
conditions, does not adopt a folded, globular structure. This property has only been
noted in a limited number of proteins. Our research on NACP has led us to
investigate this issue in more depth, and we have now identified a family of
proteins with similar physical properties, all of which are likely to be natively
denatured (Table 5.2). The proteins classified into this family have one or more of
the following properties: 1) stability to heat denaturation; 2) an abnormally high
Stokes radius upon size exclusion chromatography; 3) a highly charged (often acidic)
amino acid sequence; 4) abnormal SDS binding leading to unusual mobility on SDS-
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PAGE; and 5) random coil structure as demonstrated by CD. These properties are
consistent with a "natively denatured" structure: A highly charged amino acid
sequence interferes with SDS binding and allows the protein to be soluble in a
"denatured" state, which is, by definition, resistant to heat-induced denaturation.
The elongated nature of the molecule alters its mobility on a size-exclusion column
in comparison with globular standards. Table 5.2 presents a putative list of these
proteins based solely on a survey of existing literature.
Table 5.2 Proposed family of "natively denatured" proteins. These proteins are
characterized by one or more of the following properties: heat-stability to
denaturation; an abnormally large Stokes' radius upon size-exclusion
chromatography; an acidic amino acid sequence; or direct structural evidence, for
example CD spectroscopy, which indicates a lack of folded structure.
Large
Heat Stokes CD Indicates
Protein stable? radius? pI Random Coil? Description Ref.
NACP/a-synuclein YES YES 6.1 YES found in synapse
Jf-synuclein YES YES 5.5 NA found in synapse 11
Tau YES YES 10.4 YES promotes microtubule assembly 37Chromogranin A YES YES 5.0 YES found in chromaffin granules 38MAP2 YES no NA YES microtubule associated protein 39
DARPP-32 YES YES 4.7 YES phosphatase inhibitor 26
I1PP1, I2PP1 YES NA <7 NA phosphatase inhibitors 4011PP2A, I2 PP2A YES YES NA NA phosphatase inhibitors 41
IHPTP, ILPTP YES NA NA NA tyrosine phosphatase inhibitors 42PKA-I YES YES NA YES c-AMP dependent kinase inhibitor 43
Prothymosin a NA YES 3.5 YES found in thymus 4481K CBP YES YES 4.3 NA calmodulin binding protein 4532K inhibitor YES YES NA NA c-AMP phosphodiesterase 46
inhibitor
Of this group, the structure of prothymosin a has been the most thoroughly
characterized. CD, gel filtration, x-ray scattering, and dynamic light scattering were
all used to establish that this biologically active protein has a random coil
conformation. 44  Several other proteins included in this family are heat-stable
phosphatase inhibitors, which have not been well-characterized structurally. It is of
interest to note that 03-synuclein and tau share this structural similarity, as well as
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chromogranin A, a protein involved in secretory granule formation. Table 5.2 is by
no means comprehensive; more detailed structural studies of these and other
proteins are required to fully define the physical properties of natively denatured
proteins. It is likely that this common structural property (or lack thereof) has a
functional significance, possibly in mediating protein-protein interactions.
Identification of an NACP Binding Protein
A Natively Denatured Structure Suggested Protein-Protein Interactions.
The observed flexibility of NACP suggested that it may function via
complexation with another protein, rather than as a monomer. It is possible that
either the protein adopts a specific three-dimensional structure upon interaction
with membranes or receptor molecules, or that its nonfolded conformation might
be advantageous for interactions with other biological macromolecules. A similar
proposal has been made for the natively denatured protein prothymosin 0. 4 4 We
therefore initiated a search for endogenous NACP binding partners.
Initial efforts to identify NACP binding molecules were carried out using
affinity chromatography. 24 Recombinant NACP was immobilized by covalent
attachment of lysine residues to a polymeric matrix. Rat brain cytosolic extracts were
then passed over the beads, and SDS-PAGE was used to identify bound proteins.
This method met with limited success, and suffers from several potential
drawbacks. For example, the nonspecific attachment of lysine residues to the
column may block potential binding sites, especially binding to the lysine-rich N-
terminus of NACP. Additionally, native NACP (and not the recombinant protein)
may have a posttranslational modification which mediates binding. Affinity
chromatography, therefore, may not be the optimal method for isolating NACP
binding partners.
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Immunoprecipitation was selected as an alternative to affinity methods.
Coprecipitation is a classical method of detecting protein-protein interactions.4 7,4 8
The basic experiment involves the addition of an antibody to cell lysate or
homogenate, followed by precipitation of the antibody-antigen complex, generally
using an immunoglobulin-binding molecule immobilized on a solid support.
Analysis by SDS-PAGE allows the identification of proteins bound to the antigen.
The method has a number of distinct advantages over other methods. First, native
proteins are used in the midst of all the competing proteins found in a crude lysate,
providing an inherent control. Second, both the antigen and binding protein are
present in the same concentrations as in a cell, eliminating artifacts due to
abnormally high levels of test protein. Third, elaborate complexes, which may be
difficult to reassemble after they are dissociated, are already in their natural state and
can be readily precipitated. One disadvantage of the method is that coprecipitation is
not as sensitive as protein affinity chromatography, because the concentration of
antigen is lower than it is in protein affinity chromatography. Also, coprecipitating
proteins do not necessarily interact directly, since they can be part of a larger
complex; this can be accounted for by the use of binding experiments with purified
proteins. Finally, proteins can coprecipitate as a result of cell lysis and not reflect a
relevant physiological interaction; this can be addressed by demonstrating
colocalization of the two proteins in vivo. For the initial identification of potential
NACP binding partners, therefore, coimmunoprecipitation experiments were
undertaken.
Immunoprecipitation of NACP Leads to an Immunoreactive NACP Doublet.
A mouse monoclonal antibody to NACP was obtained from D. Clayton
(University of Illinois).7 This monoclonal antibody (H3C) is a mouse IgGi antibody
which was obtained in the form of reconstituted mouse ascites. It was raised to a
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peptide from the canary synelfin C-terminal 16 amino acid sequence. The canary
sequence differs from the rat sequence by only 2 amino acids in this region (Fig. 5.2),
and the antibody has been shown to cross-react with a rat species of the correct mass.
Monoclonal antibodies are generally less desirable for immunoprecipitation
experiments, since only one antibody molecule is able to bind to one molecule of
antigen. With polyclonal antibodies, overlapping immunoreactivity leads to more
effective precipitation. However, an immobilized antibody binding reagent such as
Protein G does allow the use of monoclonals.
Initially, we confirmed that we could use the H3C antibody to precipitate
NACP from the cytosolic fraction of crude rat brain homogenate. NACP comprises
as much as 0.5% to 1% of the total protein concentration in rat frontal cortex. 21
Stripped rat brains were homogenized and separated into cytosolic and membrane
fractions. Cytosol was incubated with antibody, followed by addition of Protein G
immobilized on sepharose beads. Protein G binds tightly and specifically to the Fc
chain of IgG1. Centrifugation followed by extensive washing of the beads was used
to isolate the immobilized NACP-antibody complex.
This procedure resulted in the identification of two bands in the -19 kDa
range, as identified by 7% SDS-PAGE. The observation of an immunoreactive
NACP doublet has been reported elsewhere.5 Western blotting indicated that both
bands correspond to immunoreactive forms of NACP. The lower band of the
doublet comigrates with recombinant NACP. N-terminal sequencing of both bands
was unsuccessful, suggesting blocked N-termini. The bands were blotted to a PVDF
membrane and eluted individually, and submitted for MALDI-TOF mass
spectrometry. MS of the lower band was unsuccessful using this technique. The
upper band showed a mass of 14,270.3. This mass may correspond to a truncated
protein comprising residues 3-140 (Calc'd mass = 14,270.0). However, any
posttranslational modifications, including acylation of the N-terminus, would affect
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this calculation. Determination of the identity of these two immunoreactive bands,
therefore, requires further experimental investigation.
A Mr~96 kDa Protein Coprecipitates with NACP
Examination of the anti-NACP immunoprecipitate on a 7% polyacrylamide
gel reveals a band with an apparent molecular weight of approximately 96 kDa. (Fig.
5.11, lane 1).24 A number of control experiments were run in order to confirm the
specificity of this interaction. Cytosol was incubated with just Protein G Sepharose
to control for nonspecific binding to the Protein G beads (Fig 5.11, lane 2). To control
for nonspecific binding to the constant regions of IgG and to control for proteins
contained in mouse ascites, cytosol was incubated with mouse monoclonal
antibodies to neurofilament 200, a common brain protein.24 The 96 kDa band
appeared in none of the above control lanes, nor was it present in the antibody
preparation itself (Fig 5.11, lane 3).
Identification of the 96 kDa band was achieved via standard microsequencing
procedures. The immunoprecipitate was run on a 7% SDS gel and blotted to a PVDF
membrane, which was stained with the reversible dye Ponceau S. Ponceau S is less
sensitive than Coomassie Blue, which has a detection limit of ~0.2-0.5 gg, 3 6 but it
does not require fixing the protein to the blot. The band of interest was excised from
the membrane and submitted for N-terminal sequencing. This procedure was
unsuccessful, indicating that this protein, as well as NACP, has a blocked amino
Figure 5.11 (following page) Coimmunoprecipitation of VCP with NACP. Cytosolic
fraction of rat brain homogenate was immunoprecipitated with antibodies to NACP
and stained with Coomassie Blue R-250 (lane 1), immunoblotted with anti-NACP
(lane 4), or immunoblotted with anti-VCP (lane 5). As controls, Protein G-
Sepharose was incubated with cytosol (lane 2) or with anti-NACP (lane 3) and
stained with Coomassie Blue R-250.
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terminus. The protein was digested directly from the membrane using
endopeptidase Lys-C. Fragments were collected as HPLC peaks, and three of these
peaks were arbitrarily submitted for sequencing. The three HPLC peaks each
contained two peptides. BLAST searches of the NIH protein sequence database49
were used to identify the proteins from which these peaks were derived. Two of the
peptides corresponded to the heavy chain of IgG, and are most likely due to antibody
contamination of the 96 kDa band. The remaining sequences are an exact match to
rat valosin-containing protein (VCP) (Figure 5.12).
VCP is a Member of a Family of ATPases
Valosin-containing protein (VCP) was first identified as the precursor to
valosin, a 25 amino acid peptide thought to act as a digestive hormone. Koller and
Brownstein identified and cloned the putative precursor, and concluded that
valosin is an artifact of purification and does not occur in vivo.50 VCP became the
first member of a family of ATPases named the AAA family, for ATPases Associated
to a variety of cellular Activities.5 1 The common feature of the AAA family is an
ATP binding module of about 230 amino acids. These proteins have been
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RELQELVQYPVEHPXK peptide 1
RELQELVQYPVEHPDK VCP 487-502
RREAVXIVLSDDT peptide 2
RREAVCIVLSDDT VCP 64-76
GDIFLVRGGMRAVEF peptide 3
GDIFLVRGGMRAVEF VCP 149-163
EMVELPLRHPA peptide 4
EMVELPLRHPA VCP 218-228
Figure 5.12 Peptide sequences from proteolytic digest of 96 kDa NACP-binding
protein. The corresponding amino acid sequences from valosin-containing protein
are indicated. X indicates an unidentified amino acid.
implicated in a variety of cellular processes, including cell cycle regulation,52 HIV-1
gene expression,53 peroxisome assembly,54 proteasome function, 55 and vesicle-
mediated transport. 14,56-59
VCP has also been called "p97 ATPase" (in Xenopus laevis oocytes)60 and
"TER ATPase" (in rat endoplasmic reticulum);14 these monikers all refer to nearly
identical proteins which are considered to be interspecies homologs (Table 5.3).
These proteins all exist as homooligomeric ring-shaped structures reminiscent of
chaperones. ATPase activity is detected only in the intact hexameric complex and
not in dissociated molecules.60 The yeast homolog, cdc48p, which is about 70%
identical to the mammalian species, is involved in cell cycle control.52 Murine VCP
was found to be tyrosine phosphorylated in response to CD4 receptor activation in
lymphocytes, also supporting a possible role in cell division.61,62
Table 5.3 Interspecies homologs of valosin-containing protein (VCP). These
proteins are considered functionally equivalent. A large number of other ATPases
also share significant sequence homology to VCP.
species name of protein homology to rat VCP
rat TER ATPase 100%
mouse VCP 99%
pig VCP 99%
X. laevis (clawed frog) p97  95%
yeast cdc48p 68%
The subcellular location of neuronal VCP has not been reported. In other cell
types, the protein is generally associated with the membrane. A soybean variant of
VCP is associated with the plasma membrane. 63 The Xenopus homolog, p97,
exhibits diffuse cytoplasmic expression in oocytes.60 Cdc48p partially localizes to the
ER membrane in yeast.57
Recently, a large number of laboratories have reported findings implicating
VCP (p97) in vesicle fusion processes. Antibodies directed against rat VCP (TER
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ATPase) blocked cell-free transfer in a system derived from rat liver endoplasmic
reticulum and prevented the ATP-induced cell-free formation of transition
vesicles.14 This result was supported recently with three consecutive papers in the
journal Cell, which demonstrated the ability of p97 to mediate regrowth of Golgi
cisternae and fusion of ER membranes. 57-59 Additionally, VCP binds to clathrin, the
structural protein associated with coated vesicles involved in receptor-mediated
endocytosis. 64 NSF (N-ethylmaleimide sensitive fusion protein),65 a mediator of
membrane fusion through a well-defined pathway, is also a member of the AAA
family, and shares a significant degree of homology with VCP (36% over residues
206-605; 49% over the ATP binding site, residues 234-414).60 These findings led to the
proposal that VCP may participate in membrane fusion via interaction with
components that may be entirely distinct from those required for NSF-mediated
events (vide infra).56
Confirmation of VCP as the 96 kDa species
VCP has a calculated molecular weight of 88,706 daltons, but has been
observed to migrate in the 95-100 kDa range on SDS-PAGE, 14 consistent with our
observation of a band at -96 kDa. To confirm the identity of the protein, we
immunoblotted with antibodies to VCP. A rabbit polyclonal antibody (serum 725)
was obtained from L. Samelson (National Institutes of Health).61 This antiserum
specifically stained a band in both crude cytosol and the anti-NACP
immunoprecipitate which comigrated with the observed 96 kDa species (Fig. 5.11,
lane 5).
ATPase activity staining 66 of non-dissociating polyacrylamide gels was used as
another method for confirming the identity of VCP. The 96 kDa band was eluted
from the immunoprecipitate with 0.5 M NaC1, and the buffer was exchanged to
remove salt. The elute, which contained nearly homogeneous 96 kDa protein, was
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run on a 6% non-dissociating polyacrylamide gel. The gel was incubated with 2 mM
MgC12 and 0.05% Pb(OAc) 2 overnight, and then was washed and treated with
sodium sulfide. ATPase activity manifested itself as a dark spot of lead sulfide in the
gel. This spot comigrated with the major Coomassie Blue-stained band, confirming
that the 96 kDa species has ATPase activity.
In Vitro Reconstitution of the NACP-VCP Interaction with Purified Proteins
The observed coprecipitation of NACP with VCP could either be due to a
direct binding interaction or could be mediated by a third species which contacts
both proteins. This issue was addressed by attempting to reconstitute the binding
interaction using purified proteins. A culture of competent E. coli transfected with
the expression vector for a GST fusion protein of VCP was obtained from L.
Samelson (NIH).62 This construct also includes a myc epitope tag at the C-terminus
of the VCP sequence. This culture was used to inoculate a large-scale culture, which
was induced as described. 62 The cells were lysed using a French press. Purification
of the GST-VCP-myc fusion protein was achieved by immobilization of the protein
on glutathione-Sepharose 4B beads, followed by glutathione elution.
In addition to providing a simple method for protein purification, the GST
fusion protein contains a handle with which to perform in vitro binding
experiments. The fusion protein was immobilized on glutathione-Sepharose beads,
and washed thoroughly to remove non-specific binders. The immobilized VCP was
then incubated with a solution of recombinant NACP. The complex was again
washed thoroughly, and the proteins bound to the beads were analyzed by SDS-
PAGE (Fig. 5.13). As a control experiment for non-specific binding to the beads,
recombinant NACP was incubated with glutathione-Sepharose under identical
conditions. As shown in Fig. 5.13, VCP formed a stable complex with NACP. A
small amount of non-specific binding to the beads was unavoidable (Fig. 5.13, lane
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3), but was minor relative to the binding to VCP. No additives were required to
reconstitute the binding interaction, indicating that NACP and VCP interact directly.
We attempted to localize the region of NACP responsible for binding VCP by
competing for binding with peptides derived from the NACP sequence. The
immobilized GST-VCP fusion protein was incubated with NACP, and one of the
following peptides in a large excess relative to NACP (50:1 except for NAC):
NACP19-48, NACP111-125, NACP96-125, and NACP61-95 (NAC, only a 1.5:1 excess
due to solubility limitations). If any of these peptides contains the VCP binding site
it should efficiently compete with NACP, and the beads should show a large
decrease in the amount of bound NACP. In fact, none of the peptides showed a
significant ability to compete with NACP for binding. This may indicate that the
VCP binding site includes residues from distal regions of the NACP sequence.
Alternatively, the binding site may simply overlap two of the peptides which we
chose to examine. A more constructive method for localizing the binding regions of
these proteins may be to use truncated and/or deletion constructs of the two
proteins in the in vitro binding experiment. A genetic screen, such as the yeast II
hybrid system, 67 would be an alternative method for answering these types of
questions.
Figure 5.13 (following page)In vitro interaction between NACP and GST-VCP
fusion protein. Lane 1, NACP bound to GST-VCP immobilized on glutathione-
Sepharose; Lane 2, immobilized GST-VCP; Lane 3, glutathione-Sepharose incubated
with NACP (control).
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Coimmunofluorescence Indicates Colocalization of NACP and VCP in Cultured
Neurons
The experiments discussed to this point have demonstrated the presence of a
NACP-VCP complex in cell-free in vitro systems. To show that this interaction
could have biological relevance, it is important to demonstrate that the proteins
have the opportunity to interact in vivo, and that the interaction does not take place
as a result of cell lysis. Two common techniques are used to determine if two
proteins share an intracellular location. The first method is to use gradient
ultracentrifugation experiments to show that the two species cosediment in a
common fraction. A more direct method for showing colocalization, and the
experiment which we carried out, is to visualize the proteins within cells using
immunofluorescence microscopy. These experiments were performed in
collaboration with Dr. Adriana Ferreira at the Harvard Medical School Center for
Neurologic Disease.
Cultured E18 hippocampal neurons grown in culture for 14 days were
immobilized, and double stained with mouse anti-NACP and rabbit anti-VCP
antibodies (Fig. 5.14).68 In this culture, axons appear as thin, tapering "processes"
which often run alongside of dendrites and extend far from cell bodies. After
treatment with the primary antibodies, the cultures were rinsed and treated with
secondary antibodies (goat anti-mouse IgG rhodamine conjugate and goat anti-rabbit
FITC conjugate). Neurons were then visualized under a fluorescence microscope;
the rhodamine appears red, the fluorescein appears green, and, using a dual FITC-
rhodamine filter, the areas of costaining appear yellow (Fig. 5.15).
A diffuse pattern of NACP and VCP immunoreactivity was observed
throughout the cell bodies, in contrast to punctate staining along the axonal
processes. NACP and VCP seem to be colocalized at these spots. Since NACP has
been shown to be highly concentrated at synapses in brain tissue sections,23 cultures
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were double-stained with antibodies to the synaptic markers synapsin 169 or
synaptophysin. Some, but not all, of the immunoreactive spots for NACP and VCP
colocalized with these synaptic markers, suggesting that NACP-VCP is enriched at
synaptic sites. To distinguish axonal and dendritic processes, we also double-labeled
with antibodies to MAP2, a somatodendritic marker, 70 and NACP. MAP2-positive
processes were not stained with NACP, confirming that NACP is not present in
dendrites.
Figure 5.14 (following page) Immunofluorescence microscopy of NACP and VCP in
cultured hippocampal neurons. NACP was visualized using rhodamine
fluorescence (panels A and D), and VCP was visualized using FITC (panels B and E).
Micrographs obtained using a dual FITC-Rhodamine filter show the colocalization
of NACP and VCP in cell bodies and along the axons (panels C and F).
139

Implications of the NACP-VCP Complex for Vesicle-Mediated Transport. Learning,
and AD
We have identified, using coimmunoprecipitation, an interaction of NACP
with VCP. Several criteria are essential to substantiate the validity of a
coimmunoprecipitation experiment.47 First, it has to be established that the
coprecipitated protein is precipitated by the antibody itself and not by a
contaminating antibody in the preparation. This problem was avoided by the use of
a monoclonal antibody. Second, it has to be established that the antibody does not
itself recognize the coprecipitated protein. We demonstrated that VCP does not
stain with anti-NACP in a Western blot. Third, it is important to determine if the
interaction is direct or proceeds through a third party. An in vitro binding
experiment with purified recombinant proteins indicated that the interaction is
specific and direct. Finally, it is critical to determine that the interaction occurs in
the cell and not as a consequence of cell lysis. Coimmunofluorescence experiments
demonstrated clear colocalization of NACP and VCP in cultured hippocampal
neurons. We have therefore demonstrated that the NACP-VCP interaction is
relevant and worthy of further investigation.
The function of the NACP-VCP complex, on the other hand, remains a
matter of speculation. A great deal of circumstantial evidence, however, indicates a
potential role of the complex in vesicle-mediated transport processes. Membrane
fusion events during intracellular transport are mediated by large complexes of
proteins." The first such protein, N-ethylmaleimide sensitive factor (NSF), was
isolated as a mediator of membrane fusion which could be inactivated by the
addition of N-ethylmaleimide. 65 Using this protein as a starting point, the basic
components of NSF-mediated membrane fusion have been elucidated. These
include the SNAPs (soluble NSF attachment proteins), soluble proteins required for
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NSF attachment to membranes, as well as the membrane-bound receptors for the
putative NSF-SNAP complex, the "SNAREs" (Fig. 5.15). Several other soluble and
membrane-bound proteins (e.g. synaptotagmin, rab3, and p115) have also been
implicated in the NSF-mediated fusion pathway.
Recently, it was noted that fusion of transport vesicles from the Golgi
complex with the plasma membrane involved a different mechanism, one that was
independent of NSF and SNAPs.56 The absence of an effect of NSF and SNAPs led
to a search for alternative mediators of membrane fusion. Specifically, VCP was
investigated based on its homology to NSF. Three independent reports indicated
that VCP (actually, either Xenopus p97 or the yeast homolog cdc48) can reconstitute
Golgi or endoplasmic reticulum transport.5 7-5 9  An alternative pathway was
proposed, in which VCP plays a similar role to that proposed for NSF, but interacts
with a completely independent set of proteins (Fig. 5.15). A review of these papers
stated, "The search is now on to identify the likely accessory molecules with which
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t-SNARE NACPNCP receptor
Figure 5.15 (a) The molecular components of NSF-mediated membrane fusion. (b)
A parallel pathway for membrane fusion proposed for VCP. NACP may be a SNAP
equivalent. Adapted from reference 56.
ýs P?
p97/cdc48p interacts, the functional analogs of SNAPs and SNAREs."5 6 We have
shown that NACP interacts with VCP, and that the two proteins colocalize in
synapses. It seems likely, therefore, that NACP is the first of such SNAP analogs to
be discovered. Confirmation of this proposal will require the direct experimental
demonstration that NACP has the ability to mediate membrane fusion.
Based on the proposal that the NACP-VCP complex plays a role in membrane
fusion events in neurons, we can begin to speculate on the relationship of these
proteins to learning and AD. The brain of a learning animal is characterized by
upregulation of NACP, 7 consistent with the idea that NACP-VCP dependent vesicle
trafficking may be involved in synapse formation or stabilization. A function of
NACP in mediating "synaptic plasticity" has already been proposed.7 The AD brain,
in contrast, is characterized by a significant loss of synapses in proportion to the
severity of cognitive impairment. 23,72,73 The slightly reduced expression of NACP
could confer susceptibility to AD, by decreasing the stability of synapses or by
increasing the sensitivity of synapses to neurotoxic agents. Alternatively, the
NACP-VCP complex could directly affect an AD pathogenic pathway, such as the
intracellular production74 or nucleation 75 of A1. The results presented here suggest
future experiments which may define more clearly the molecular events underlying
learning and AD.
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Experimental Section
Protein Expression
NACP Expression and Purification. A pRK172 plasmid containing the
human NACP (a-synuclein) sequence (provided by R. Jakes and M. Goedert, MRC,
Cambridge, UK) was dissolved in TE buffer (10 mM Tris, pH 8.0, 0.1 mM EDTA) and
added to 25 pgL of competent BL21(DE3) E. coli cells. The cells were incubated on ice
for 30 min, heat shocked at 42"C for 30 s, and then incubated at RT for 2 min. To the
cells was added 500 giL of sterile Luria-Bertani Broth (LB) containing 0.2% glucose
which had been prewarmed to 37"C. After incubation at 37"C for 1 h, 200 gL of the
bacteria was plated onto ampicillin positive agar plates. The bacteria was grown for
17 h at 37"C. A control plate (competent cells lacking the plasmid) did not grow
colonies. Two colonies were chosen, and each was used to inoculate a stab culture,
which was grown for 36 h and stored at -80"C. All cultures were henceforth grown
from only one of these stab cultures.
The stab culture was used to inoculate 10 mL of sterile Luria-Bertani Broth
(LB) containing ampicillin (50-100 gg/mL), which was incubated at 37"C with
shaking overnight (12 h). A portion of this culture (5 mL) was used to inoculate 500
mL of LB-ampicillin, which was shaken at 37"C until the O.D. (600nm) reached 0.6
to 1.0 (-3 h). 120 jgL of Isopropyl-l-thio-o3-galactoside (1.68 M in H20) was added
(final concentration = 0.4 mM) to induce protein expression. After shaking for 4 h at
37"C (induction levels were monitored by SDS-PAGE), the cells were collected by
centrifugation (30 min at 24,000 x g), resuspended in 20 mL of lysis buffer (50 mM
Tris-HC1, pH 7.4, 0.1 mM DTT, 0.1 mM phenylmethysulfonyl fluoride (PMSF)), and
lysed using a French press at 16,000 p.s.i. The lysate was centrifuged at 24,000 x g for
30 min, and the pellet was discarded. 6 mL of 5% streptomycin sulfate (0.2 volumes)
in lysis buffer was added, and the solution was stirred on ice. The resultant
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suspension was centrifuged at 24,000 x g for 30 min, the supernatant was transferred
to a plastic centrifuge tube, and the pellet was discarded. The supernatant was then
immersed in a boiling water bath for 10 minutes, and the resultant suspension was
cooled to RT and centrifuged at 24,000 x g for 30 min. The supernatant was loaded
onto 25 g of Biogel P-10 (100-200 pm wet), eluted with lysis buffer (Rv=65 mL),
dialyzed with several changes against ddH 20 overnight (Spectrapor 1 tubing, MW
cut-off = 6,000-8,000), and lyophilized to a white solid. HPLC and SDS-PAGE
indicated the protein was >90% pure. Analytical HPLC (C4 reversed-phase, Vydac):
2.0 mL/min, 70/30 H20/CH3CN, (0.1% TFA), linear gradient to 60/40 (20 min),
Rv=31mL. MALDI-TOFMS: (M + H)+ calcd for C627H 1013N 1660 216S4 14461.2, found
14463.0 (+ 4.6). Amino acid analysis: Asx 10.1 (9), Glx 24.9 (24), Ser 4.6 (4), Gly 18.2
(18), His 1.8 (1), Thr 10.4 (10), Ala 19 (19), Tyr 3.5 (4), Val 15.4 (19), Met 3.6 (4), Ile 2.4
(2), Leu 4.7 (4), Phe 5.2 (5), Lys 16.6 (15). Tryptic digest: To -1 mg of NACP
(determined by absorbance, using an estimated E274 of 5600 M-1cm -1 based on the
tyrosine content of the protein) was added 500 gL of trypsin (0.04 mg/mL in 0.1M
NH 4HCO 3). The solution was incubated at 37"C for 80 min, and loaded directly onto
a PDMS target. PDMS: 688.6 (residues 97-102), 773.0 (1-6), 830.8 (24-32), 874.0 (13-
21),968.3, 1156.7 (1-10), 1252.2, 1296.9 (46-58), 1523.9 (46-60 and 44-58), 1930.0 (61-80),
2158.1 (59-80). Additional minor peaks were also detected. Alternate Purification
Method. NACP was purified without the use of a boiling step via a documented
procedure.24
GST-VCP-myc Expression. An E. coli culture (DH5a strain competent cells)
transformed with a plasmid containing the murine VCPmyc cDNA subcloned into
the BamHI/SmaI sites of pGEX-3X (Pharmacia LKB Biotechnology Inc.) was obtained
from L. Samelson (NIH, Bethesda, MD). 62 100 pgL of this culture was used to
inoculate 50 mL of sterile LB-amp medium (100 pgg/mL ampicillin) in a 250 mL
Erlenmeyer flask, which was shaken overnight (18 h). Four aliquots of 0.5 mL were
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removed and added to 0.5 mL of 30% glycerol; these tubes were frozen and stored at
-80"C for future use. Additionally, 1.5 mL was removed for DNA isolation. 5 mL of
the remainder was used to inoculate 500 mL of LB-amp, which was shaken in a 2L
flask at 37"C until the O.D. (600 nm) reached 0.6 - 1.0. 500 gL of IPTG (24 mg/mL in
H20) was added, and the cells were shaken at 37*C for 70 min, and centrifuged for 10
min at 6000 x g. The supernatant was discarded, and the cells were resuspended in
20 mL of "GST lysis buffer" (50 mM Tris-HC1, 150 mM NaC1, pH 7.5, 2 mM EDTA, 2
mM MgC12, 0.5 mM DTT, 0.5 mM ATP, 0.5% Triton X-100, 10 ptg/mL leupeptin, 5
jgg/mL aprotinin, 0.1 mM PMSF) and lysed using a French press at 16,000 p.s.i. The
lysate was centrifuged at 24,000 x g for 30 min. Glycerol (10% final concentration)
was added to the supernatant, which was aliquotted into 1 to 1.5 mL portions and
stored at -80"C until further use.
General Procedures for Polyacrylamide Gel Electrophoresis
Novex minigels (1.0 or 1.5 mm) were used throughout this work. All single
percentage gels were poured with a 4% stacking gel (SDS or native) and run at 100-
140V. All 1.0 mm gradient gels were purchased from Novex. Bis-acrylamide (40%
solution, 29:1 acrylamide/bis) was purchased from BioRad. Running buffer: 24 mM
Tris, 192 mM glycine, 0.1% SDS, pH 8.3. Sample loading buffer: 125 mM Tris-HC1,
pH 6.8, 15 mM EDTA, 20% glycerol, 10% w/v SDS, 4% P-mercaptoethanol, 1 mg/mL
bromophenol blue.
Western blotting. Gels were transferred to PVDF membranes (BioRad) using a
semi-dry transfer apparatus (Hoefer) at 100 mA for 45-50 min. The membrane was
transferred to a plastic centrifuge tube, blocked with 5% nonfat dry milk in blotting
buffer (50 mM Tris-HC1, 150 mM NaCl, pH 7.5) (RT, 20 min with gentle rotation).
The blocking buffer was removed without washing, and primary antibody was
diluted in buffer (1:100,000 for anti-NACP; 1:250 for anti-VCP) and incubated with
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the blot (RT, 2 h). The blot was washed (1 x 1 min, 3 x 3 min) with transfer buffer,
and incubated with secondary antibody (goat anti-mouse IgG-alkaline phosphatase
conjugate (Sigma), 1:4000 dilution for NACP; goat anti-rabbit IgG-alkaline
phosphatase conjugate (Sigma), 1:15,000 for VCP) (RT, 1 h). The blot was washed
again with buffer (1 x 1 min, 3 x 5 min) and incubated with 5-bromo-4-chloro-3-
indolyl-phosphate/Nitro blue tetrazolium (Sigma FASTTM BCIP/NBT, 1 tablet in 10
mL transfer buffer) until color development was complete.
Preparation of Samples for Amino Acid Sequencing. The anti-NACP
immunoprecipitate was run on SDS-PAGE, blotted to PVDF, and stained with
Ponceau S. Bands were excised using a clean razor blade, and submitted directly for
either N-terminal sequencing or proteolytic digestion followed by sequencing.
Coomassie Blue Staining (gels). Gels were immersed in Coomassie Blue stain (2.5
g/L Coomassie Blue R-250, 40% MeOH, 7% AcOH) for at least 20 min, followed by
fast destain (5% AcOH, 25% MeOH) for 30 to 120 min and then slow destain (14%
AcOH, 10% MeOH) overnight.
Coomassie Blue Staining (blots). Blots were immersed in stain (0.025% Coomassie
Blue R-250, 60% AcOH, 40% MeOH) for 1 min, followed by destain (50% MeOH, 10%
AcOH) for -1 min or until bands became visible.
Ponceau S Staining (blots). Blots were incubated with 0.2 % Ponceau S in 1% AcOH
for 1 min, and destained in H20 for -1 min or until bands became visible.
Silver Staining (gels). Gels were 1) Fixed for at least 1 h (50% MeOH, 12% AcOH, 0.5
mL 37% formaldehyde/L) ; 2) Washed 3 x 20 min with 50% EtOH; 3) Pretreated for 1
min with Na2S203*5H20 (0.2 g/L); 4) Rinsed with H20 3 x 20 sec; 5) Impregnated for
20 min (2 g/L AgNO3, 0.75 mL 37% formaldehyde/L); 6) Rinsed with H20 2 x 20 sec;
7) Developed for -10 min (or until bands became visible) (60 g/L Na2CO 3, 0.5 mL
37% formaldehyde/L, 4 mg/L Na2S203*5H20); 8) Washed 2 x 2 min with H20; and
9) Stopped with 50% MeOH, 12% AcOH for 10 min. Gels were stored in gel drying
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solution.
Ferguson Plot27
The following proteins were run on 6%, 10%, and 14% non-dissociating
polyacrylamide gels: NACP, BSA (MW = 68,000), pepsin (35,000), insulin (5733). Rf
(6%, 10%, 14%): BSA 0.71, 0.27, 0.13; pepsin 0.69, 0.32, 0.16; insulin 0.86, NA, 0.40;
NACP 0.52, 0.29, 0.17. For each protein, Kr was calculated as the slope of a plot of
logRf vs. % acrylamide: BSA, -0.0938; pepsin, -0.0800; insulin, -0.0417; NACP, -0.0608.
A plot of Kr vs. MW was used to extrapolate an approximate MW of 19,000 for
NACP.
Circular Dichroism Spectroscopy
Samples for CD were prepared by dissolving recombinant NACP in 300 gL of
either Tris buffer (10 mM Tris-HC1, pH 7.5), PBS (10 mM sodium phosphate, 100 mM
NaC1, pH 7.4), or acetate buffer (50 mM NaOAc, 100 mM NaC1, pH 4.5). Spectra were
recorded on a Jasco J-500 Spectropolarimeter, in a 0.1 cm quartz cell. The following
parameters were used: Band width = 1.0 nm; slit width = "auto"; time constant = 16
sec; step resolution = 0.4 nm; scan speed = 10 nm/min. The sensitivity was varied
according to the observed intensity of each spectrum. Observed ellipticity (00bs) was
converted to mean residue ellipticity (OMRW, in deg.cm 2 /dmole) by the following
equation:
0 MRW = (0obs x 100,000)/(c x 1 x n)
where c = concentration (in giM), 1 = path length (in cm), and n = number of residues
in the protein. The percentages of secondary structural elements were estimated
based on the method of Greenfield and Fasman,28 using the following formulae:
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% a helix = [-OMRW(@ 2 08 nm) - 4000]/290
% 3 sheet = -[OMRW(@ 22 2 nm) + 396 (%a) - 3900]/177
% coil = 100 - %a - %3
Data shown is an average of at least three runs.
Other Spectroscopic Methods
FTIR was performed on a Perkin-Elmer 1600 series spectrometer. Solution
spectra were recorded using a solution cell with CaF2 plates (0.05 mm Teflon spacer).
The FTIR spectrum of recombinant NACP (4 mg/mL in D20) was recorded, and the
spectrum of D20 alone was subtracted. UV spectra were recorded on a HP8452A
UV/vis spectrophotometer.
Preparation of Rat Brain Cytosolic Extract
Ten stripped rat brains (PelFreez, Rogers, AR) were homogenized in 80 mL of
lysis buffer (50 mM Tris-HC1, pH 7.4, 1 mM EDTA, 0.1 mM DTT, 0.1 mM PMSF)
using 2 x 30 second bursts on a Polytron at setting 5. The homogenate was
centrifuged at 800 x g for 10 min, and the supernatant was centrifuged at 100,000 x g
for 1 h to separate cytosolic and membrane fractions. Total protein concentration in
the cytosolic fraction was 6.8 mg/mL, as determined by the BCA protein
concentration assay (Pierce).
Immunoprecipitation of NACP
Rat brain cytosolic extract (1.5 mL) was prescreened with 200 gL of a 1:1 slurry
of Protein G-Sepharose (Gammabind Plus, Pharmacia), incubated for 1 h at 4"C with
4 mL of a mouse monoclonal antibody to the C-terminus of canary synelfin
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(residues 129-143) (kindly provided by D. Clayton, University of Illinois),7 followed
by incubation with 200 igL bead slurry with gentle agitation for 1-2 h at 4". Beads
were washed 3x with lysis buffer and boiled in SDS-PAGE sample loading buffer.
ATPase Activity Staining of VCP
VCP was eluted from the immunoprecipitate using 0.5 M NaC1. This sample
was run on a 6% non-dissociating polyacrylamide gel, which was incubated with
ATPase buffer (24 mM Tris, 192 mM glycine, pH 8.3; 2mM ATP, 2 mM MgC12; 0.05%
Pb(OAc) 2 *3H 20) for 18 h at room temperature. The gel was washed thoroughly
with distilled H 20 and immersed in a solution of 0.5% sodium sulfide. ATPase
activity was manifested as a dark brown precipitate in the gel. After prolonged
incubation in this solution, the gel became soft and unmanageable.
In Vitro Binding Experiments
A 50% slurry of glutathione-Sepharose 4B (50 gL) (Pharmacia) was washed 3x
with binding buffer (50 mM Tris-HC1, pH 7.4, 0.1 mM DTT, 1 mM EDTA) and
incubated with crude GST-VCP cell lysate (50 gL) with gentle agitation at 4"C for 1 h.
Beads were washed thoroughly with buffer, until no significant A280 was observed
in the wash. Recombinant NACP (50 gL of a 200 giM solution in binding buffer) was
added, the suspension was agitated at 4" for 2-3 h, the beads were washed 3 - 5 x with
buffer and boiled in SDS gel loading buffer. As a control experiment, NACP (200
gM) was incubated with glutathione-Sepharose 4B. A small amount of non-specific
binding of NACP to the beads in the control experiment could not be avoided, even
upon addition of 50-100 mM NaCl or 0.05% Tween-20 to the binding buffer.
Samples were loaded on 12% SDS-PAGE and silver-stained.
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Peptide Competition Experiments
50 giL of a 1:1 slurry of GST-VCP immobilized on glutathione Sepharose 4B
was incubated at 4°C overnight with 25 gL of NACP (-40 giM) and 25 gL of either 1)
NACP19-48 (1.8 mM); 2) NACP111-125 (2 mM); 3) NACP96-125 (2 mM); 4) NACP61-
95 (NAC, 60 gM); or 5) buffer (control). Peptides NACP19-48 and NAC were N-
terminally biotinylated. The beads were washed 3 x 1mL with binding buffer, and
boiled in 20 giL of 2x SDS gel loading buffer. 20 giL of each sample was loaded onto a
12% SDS gel and the gel was silver-stained. No competition, as evidenced by a
decrease in the intensity of the bound NACP band, was observed.
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